Curcumin reduces COVID-19 risk: real-time meta analysis of 28 studies

@CovidAnalysis, July 2025, Version 44
https://c19early.org/tmeta.html

Abstract

Significantly lower risk is seen for mortality, ventilation, hospitalization, progression, recovery, and viral clearance. 19 studies from 17 independent teams in 9 countries show significant benefit.

Meta analysis using the most serious outcome reported shows 41% [30-50%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies.

Results are very robust — in exclusion sensitivity analysis 27 of 28 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.

Studies typically use advanced formulations for greatly improved bioavailability.

No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Dietary sources may be preferred. The quality of non-prescription supplements varies widely [1-3]. All data and sources to reproduce this analysis are in the appendix.

4 other meta analyses show significant improvements with curcumin for mortality [4-7], hospitalization [4,7], recovery [6], and symptoms [4].





CURCUMIN FOR COVID-19 — HIGHLIGHTS

Curcumin reduces risk with very high confidence for mortality, hospitalization, recovery, and in pooled analysis, high confidence for ventilation, progression, and viral clearance, and low confidence for ICU admission.

Studies typically use advanced formulations for greatly improved bioavailability.

16th treatment shown effective in February 2021, now with $p = 0.0000000061$ from 28 studies.

Real-time updates and corrections with a consistent protocol for 172 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.

28 curcumin COVID-19 studies

c19early.org
July 2025

	Improvement	RR [CI]		Treatment	Control
Saber-Moghaddam	94%	0.06 [0.00-0.93]	progression	0/21	8/20
Aldwihi	31%	0.69 [0.43-1.04]	hosp.	30/144	207/594
Pawar (DB RCT)	82%	0.18 [0.04-0.79]	death	2/70	11/70
Ahmadi (DB RCT)	86%	0.14 [0.01-2.65]	hosp.	0/30	3/30
Sankhe (RCT)	89%	0.11 [0.01-2.03]	death	0/87	4/87
Majeed (DB RCT)	66%	0.34 [0.01-8.09]	ventilation	0/45	1/47
Khan (RCT)	33%	0.67 [0.37-1.19]	no recov.	10/25	15/25
Askari (DB RCT)	26%	0.74 [0.43-1.25]	no recov.	13 (n)	13 (n)
Chitre (DB RCT)	11%	0.89 [0.79-0.99]	recov. time	89 (n)	86 (n)
Din Ujjan (RCT)	29%	0.71 [0.50-1.03]	no recov.	15/25	21/25
Kishimoto (DB RCT)	47%	0.53 [0.10-2.90]	progression	2/71	4/67
Alcântara	37%	0.63 [0.16-2.41]	hosp.	3/58	6/73
Early treatment	**29%**	0.71 [0.58-0.88]		62/678	280/1,137

$Tau^2 = 0.03$, $I^2 = 29.4\%$, $p = 0.0014$

	Improvement	RR [CI]		Treatment	Control
Valizadeh (DB RCT)	50%	0.50 [0.18-1.40]	death	4/20	8/20
Tahmasebi (DB RCT)	83%	0.17 [0.02-1.32]	death	1/40	6/40
Hassania.. (DB RCT)	-46%	1.46 [0.01-329]	SpO2 imp.	20 (n)	20 (n)
Asadirad (RCT)	26%	0.74 [0.26-2.12]	death	5/27	6/24
Kartika	41%	0.59 [0.35-1.00]	hosp. time	139 (n)	107 (n)
Hartono (RCT)	53%	0.47 [0.32-0.68]	viral+	14/30	30/30
Thomas (DB RCT)	44%	0.56 [0.34-0.91]	improv.	74 (n)	73 (n)
Sankhe (SB RCT)	86%	0.14 [0.01-2.71]	death	0/60	3/60
Hellou (DB RCT)	77%	0.23 [0.06-0.95]	NEWS2	33 (n)	17 (n)
Abbaspour-A.. (RCT)	71%	0.29 [0.06-1.26]	death	2/30	7/30
Sadeghiz.. (DB RCT)	92%	0.08 [0.01-0.68]	progression	0/21	6/21
Gérain (RCT)	67%	0.33 [0.01-7.70]	death	0/25	1/24
Ahmadi (DB RCT)	58%	0.42 [0.17-1.01]	oxygen	5/29	16/39
Late treatment	**51%**	0.49 [0.39-0.61]		31/548	83/505

$Tau^2 = 0.00$, $I^2 = 0.0\%$, $p < 0.0001$

	Improvement	RR [CI]		Treatment	Control
Bejan	59%	0.41 [0.17-1.00]	hosp.	148 (n)	9,600 (n)
Shehab	42%	0.58 [0.14-2.32]	severe case	2/32	24/221
Nimer	31%	0.69 [0.45-1.04]	hosp.	29/329	179/1,819
Prophylaxis	**36%**	0.64 [0.45-0.89]		31/509	203/11,640

$Tau^2 = 0.00$, $I^2 = 0.0\%$, $p = 0.008$

All studies	**41%**	0.59 [0.50-0.70]		124/1,735	566/13,282



[1] OT: comparison with other treatment
[2] CT: study uses combined treatment

$Tau^2 = 0.05$, $I^2 = 36.3\%$, $p < 0.0001$

Effect extraction pre-specified
(most serious outcome, see appendix)



***Figure 1.* A. Random effects meta-analysis.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix. **B. Timeline of results in curcumin studies.** The marked dates indicate the time when efficacy was known with a statistically significant improvement of ≥10% from ≥3 studies for pooled outcomes, one or more specific outcome, pooled outcomes in RCTs, and one or more specific outcome in RCTs. Efficacy based on RCTs only was delayed by 2.9 months, compared to using all studies. Efficacy based on specific outcomes was delayed by 2.4 months, compared to using pooled outcomes.

Introduction

Immediate treatment recommended

SARS-CoV-2 infection primarily begins in the upper respiratory tract and may progress to the lower respiratory tract, other tissues, and the nervous and cardiovascular systems, which may lead to cytokine storm, pneumonia, ARDS, neurological injury[9-21] and cognitive deficits[12,17], cardiovascular complications[22-26], organ failure, and death. Even mild untreated infections may result in persistent cognitive deficits[27]—the spike protein binds to fibrin leading to fibrinolysis-resistant blood clots, thromboinflammation, and neuropathology. Minimizing replication as early as possible is recommended.



***Figure 2.* SARS-CoV-2 spike protein fibrin binding leads to thromboinflammation and neuropathology, from[8].**

Many treatments are expected to modulate infection

SARS-CoV-2 infection and replication involves the complex interplay of 100+ host and viral proteins and other factors[A,28-35], providing many therapeutic targets for which many existing compounds have known activity. Scientists have predicted that over 9,000 compounds may reduce COVID-19 risk[36], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications.

Extensive supporting research

In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spike[B,37-43] (and specifically the receptor binding domain[C,44-47]), M^{pro}[D,38,39,41-43,45-55], RNA-dependent RNA polymerase[E,42,43,46,47,56], PLpro[F,42], ACE2[G,40,54,57], nucleocapsid[H,58,59], nsp10[I,59], and helicase[J,60] proteins, and inhibition of spike-ACE2 interaction[K,61]. *In Vitro* studies demonstrate inhibition of the spike[B,62] (and specifically the receptor binding domain[C,63]), M^{pro}[D,55,62,64,65], ACE2[G,63], and TMPRSS2[L,63] proteins, and inhibition of spike-ACE2 interaction[K,61,66]. *In Vitro* studies demonstrate efficacy in Calu-3[M,67], A549[N,62], 293T[O,68], HEK293-hACE2[P,65,69], 293T/hACE2/TMPRSS2[Q,70], Vero E6[R,39,46,52,62,67,69,71-73], and SH-SY5Y[S,74] cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants[44], decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells[73], alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative

stress[68], may limit COVID-19 induced cardiac damage by inhibiting the NF-κB signaling pathway which mediates the profibrotic effects of the SARS-CoV-2 spike protein on cardiac fibroblasts[23], and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity[75].

Analysis

We analyze all significant controlled studies of curcumin for COVID-19. Search methods, inclusion criteria, effect extraction criteria (more serious outcomes have priority), all individual study data, PRISMA answers, and statistical methods are detailed in Appendix 1. We present random effects meta-analysis results for all studies, studies within each treatment stage, individual outcomes, peer-reviewed studies, Randomized Controlled Trials (RCTs), and higher quality studies.

Treatment timing

Figure 3 shows stages of possible treatment for COVID-19. Prophylaxis refers to regularly taking medication before becoming sick, in order to prevent or minimize infection. Early Treatment refers to treatment immediately or soon after symptoms appear, while Late Treatment refers to more delayed treatment.



Figure 3. Treatment stages.

Mechanisms of Action

Table 1 shows potential mechanisms of action for the treatment of COVID-19 using curcumin.

3CL^{pro} inhibitor	Curcumin inhibits SARS-CoV-2 3CL^{pro} [38,39,45,46,48-55,62,64,65].
RdRp inhibitor	SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibition [46,56].
ACE2 inhibitor	Curcumin inhibits ACE2 activity. SARS-CoV-2 viral entry requires host cell surface proteins ACE2 and TMPRSS2 [76,77].
TMPRSS2 downregulation	Curcumin downregulates transmembrane serine protease 2 (TMPRSS2). SARS-CoV-2 viral entry requires host cell surface proteins ACE2 and TMPRSS2 [63].
Cathepsin L inhibitor	Curcumin inhibits cathepsin L activity. Cathepsin L plays a key role in viral entry [63].
Anti-inflammatory	Curcumin shows anti-inflammatory effects [73,78-82].
Inhibition in Vero E6 cells demonstrated	*In Vitro* research shows curcumin inhibits SARS-CoV-2 in Vero E6 cells [39,46,52,62,67,69,71-73].
Inhibition in Calu-3 cells demonstrated	*In Vitro* research shows curcumin inhibits SARS-CoV-2 in Calu-3 cells [67].

Table 1. **Curcumin mechanisms of action.**

Preclinical Research

In Silico studies predict inhibition of SARS-CoV-2 with curcumin or metabolites via binding to the spike [B,37-43] (and specifically the receptor binding domain [C,44-47]), M^{pro} [D,38,39,41-43,45-55], RNA-dependent RNA polymerase [E,42,43,46,47,56], PLpro [F,42], ACE2 [G,40,54,57], nucleocapsid [H,58,59], nsp10 [I,59], and helicase [J,60] proteins, and inhibition of spike-ACE2 interaction [K,61]. *In Vitro* studies demonstrate inhibition of the spike [B,62] (and specifically the receptor binding domain [C,63]), M^{pro} [D,55,62,64,65], ACE2 [G,63], and TMPRSS2 [L,63] proteins, and inhibition of spike-ACE2 interaction [K,61,66]. *In Vitro* studies demonstrate efficacy in Calu-3 [M,67], A549 [N,62], 293T [O,68], HEK293-hACE2 [P,65,69], 293T/hACE2/TMPRSS2 [Q,70], Vero E6 [R,39,46,52,62,67,69,71-73], and SH-SY5Y [S,74] cells. Curcumin is predicted to inhibit the interaction between the SARS-CoV-2 spike protein receptor binding domain and the human ACE2 receptor for the delta and omicron variants [44], decreases pro-inflammatory cytokines induced by SARS-CoV-2 in peripheral blood mononuclear cells [73], alleviates SARS-CoV-2 spike protein-induced mitochondrial membrane damage and oxidative stress [68], may limit COVID-19 induced cardiac damage by inhibiting the NF-κB signaling pathway which mediates the profibrotic effects of the SARS-CoV-2 spike protein on cardiac fibroblasts [23], and inhibits SARS-CoV-2 ORF3a ion channel activity, which contributes to viral pathogenicity and cytotoxicity [75].

28 *In Silico* studies support the efficacy of curcumin [37-54,56-59,61,65,68,83-85].

26 *In Vitro* studies support the efficacy of curcumin [23,39,41,43,46,52,55,60-75,86-88].

An *In Vivo* animal study supports the efficacy of curcumin [41].

4 studies investigate novel formulations of curcumin that may be more effective for COVID-19 [46,87,89,90].

Preclinical research is an important part of the development of treatments, however results may be very different in clinical trials. Preclinical results are not used in this paper.

Results

Table 2 summarizes the results for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes. Table 3 shows results by treatment stage. Figure 4 plots individual results by treatment stage. Figure 5, 6, 7, 8, 9, 10, 11, 12, and 13 show forest plots for random effects meta-analysis of all studies with pooled effects, mortality results, ventilation, ICU admission, hospitalization, progression, recovery, viral clearance, and peer reviewed studies.

	Relative Risk	Studies	Patients
All studies	0.59 [0.50-0.70] ****	28	10K
After exclusions	0.62 [0.52-0.74] ****	26	10K
Peer-reviewed	0.59 [0.49-0.71] ****	26	10K
RCTs	0.56 [0.44-0.71] ****	21	1,712
Mortality	0.37 [0.22-0.64] ***	8	714
Ventilation	0.20 [0.05-0.75] *	4	435
ICU admission	0.22 [0.04-1.27]	2	169
Hospitalization	0.73 [0.66-0.82] ****	13	10K
Recovery	0.61 [0.51-0.72] ****	17	1,240
Viral	0.63 [0.44-0.90] *	6	389
RCT mortality	0.37 [0.22-0.64] ***	8	714
RCT hospitalization	0.80 [0.71-0.91] ***	7	557

Table 2. **Random effects meta-analysis for all stages combined, for Randomized Controlled Trials, for peer-reviewed studies, after exclusions, and for specific outcomes.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ ** $p<0.01$ *** $p<0.001$ **** $p<0.0001$.

	Early treatment	Late treatment	Prophylaxis
All studies	0.71 [0.58-0.88] **	0.49 [0.39-0.61] ****	0.64 [0.45-0.89] **
After exclusions	0.71 [0.58-0.88] **	0.50 [0.37-0.66] ****	0.63 [0.42-0.94] *
Peer-reviewed	0.71 [0.57-0.88] **	0.46 [0.36-0.60] ****	0.64 [0.45-0.89] **
RCTs	0.74 [0.59-0.93] **	0.46 [0.36-0.60] ****	
Mortality	0.16 [0.04-0.61] **	0.44 [0.24-0.81] **	
Ventilation	0.28 [0.05-1.65]	0.12 [0.02-0.97] *	
ICU admission		0.22 [0.04-1.27]	
Hospitalization	0.70 [0.55-0.90] **	0.76 [0.66-0.87] ***	0.63 [0.42-0.94] *
Recovery	0.69 [0.58-0.81] ****	0.42 [0.28-0.63] ****	
Viral	0.64 [0.33-1.26]	0.57 [0.42-0.78] ***	
RCT mortality	0.16 [0.04-0.61] **	0.44 [0.24-0.81] **	
RCT hospitalization	0.68 [0.27-1.69]	0.78 [0.67-0.90] ***	

Table 3. **Random effects meta-analysis results by treatment stage.** Results show the relative risk with treatment and the 95% confidence interval. * $p<0.05$ ** $p<0.01$ *** $p<0.001$ **** $p<0.0001$.



Figure 4. **Scatter plot showing the most serious outcome in all studies, and for studies within each stage.** Diamonds shows the results of random effects meta-analysis.



Figure 5. **Random effects meta-analysis for all studies.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Figure 6. Random effects meta-analysis for mortality results.



Figure 7. Random effects meta-analysis for ventilation.



Figure 8. Random effects meta-analysis for ICU admission.



Figure 9. Random effects meta-analysis for hospitalization.



Figure 10. Random effects meta-analysis for progression.



Figure 11. Random effects meta-analysis for recovery.



Figure 12. Random effects meta-analysis for viral clearance.



Figure 13. **Random effects meta-analysis for peer reviewed studies.** Effect extraction is pre-specified, using the most serious outcome reported, see the appendix for details. Analysis validating pooled outcomes for COVID-19 can be found below. *Zeraatkar et al.* analyze 356 COVID-19 trials, finding no significant evidence that preprint results are inconsistent with peer-reviewed studies. They also show extremely long peer-review delays, with a median of 6 months to journal publication. A six month delay was equivalent to around 1.5 million deaths during the first two years of the pandemic. Authors recommend using preprint evidence, with appropriate checks for potential falsified data, which provides higher certainty much earlier. *Davidson et al.* also showed no important difference between meta analysis results of preprints and peer-reviewed publications for COVID-19, based on 37 meta analyses including 114 trials.

Randomized Controlled Trials (RCTs)

Figure 14 shows a comparison of results for RCTs and observational studies. Random effects meta analysis of RCTs shows 44% improvement, compared to 36% for other studies. Figure 15, 16, and 17 show forest plots for random effects meta-analysis of all Randomized Controlled Trials, RCT mortality results, and RCT hospitalization results. RCT results are included in Table 2 and Table 3.



Figure 14. Results for RCTs and observational studies.

RCTs have many potential biases

RCTs help to make study groups more similar and can provide a higher level of evidence, however they are subject to many biases[93], and analysis of double-blind RCTs has identified extreme levels of bias[94]. For COVID-19, the overhead may delay treatment, dramatically compromising efficacy; they may encourage monotherapy for simplicity at the cost of efficacy which may rely on combined or synergistic effects; the participants that sign up may not reflect real world usage or the population that benefits most in terms of age, comorbidities, severity of illness, or other factors; standard of care may be compromised and unable to evolve quickly based on emerging research for new diseases; errors may be made in randomization and medication delivery; and investigators may have hidden agendas or vested interests influencing design, operation, analysis, reporting, and the potential for fraud. All of these biases have been observed with COVID-19 RCTs. There is no guarantee that a specific RCT provides a higher level of evidence.

Conflicts of interest for COVID-19 RCTs

RCTs are expensive and many RCTs are funded by pharmaceutical companies or interests closely aligned with pharmaceutical companies. For COVID-19, this creates an incentive to show efficacy for patented commercial products, and an incentive to show a lack of efficacy for inexpensive treatments. The bias is expected to be significant, for example *Als-Nielsen et al.* analyzed 370 RCTs from Cochrane reviews, showing that trials funded by for-profit organizations were 5 times more likely to recommend the experimental drug compared with those funded by nonprofit organizations. For COVID-19, some major philanthropic organizations are largely funded by investments with extreme conflicts of interest for and against specific COVID-19 interventions.

RCTs for novel acute diseases requiring rapid treatment

High quality RCTs for novel acute diseases are more challenging, with increased ethical issues due to the urgency of treatment, increased risk due to enrollment delays, and more difficult design with a rapidly evolving evidence base. For COVID-19, the most common site of initial infection is the upper respiratory tract. Immediate treatment is likely to be most successful and may prevent or slow progression to other parts of the body. For a non-prophylaxis RCT, it makes sense to provide treatment in advance and instruct patients to use it immediately on symptoms, just as some governments have done by providing medication kits in advance. Unfortunately, no RCTs have been done in this way. Every treatment RCT to date involves delayed treatment. Among the 172 treatments we have analyzed, 67% of RCTs involve very late treatment 5+ days after onset. No non-prophylaxis COVID-19 RCTs match the potential real-world use of early treatments. They may more accurately represent results for treatments that require visiting a medical facility, e.g., those requiring intravenous administration.

Observational studies have been shown to be reliable

Evidence shows that observational studies can also provide reliable results. *Concato et al.* found that well-designed observational studies do not systematically overestimate the magnitude of the effects of treatment compared to RCTs. *Anglemyer et al.* analyzed reviews comparing RCTs to observational studies and found little evidence for significant differences in effect estimates. We performed a similar analysis across the 172 treatments we cover, showing no significant difference in the results of RCTs compared to observational studies, RR 0.98 [0.92-1.05][99]. Similar results are found for all low-cost treatments, RR 1.00 [0.91-1.09]. High-cost treatments show a non-significant trend towards RCTs showing greater efficacy, RR 0.92 [0.84-1.02]. Details can be found in the supplementary data. *Lee et al.* showed that only 14% of the guidelines of the Infectious Diseases Society of America were based on RCTs. Evaluation of studies relies on an understanding of the study and potential biases. Limitations in an RCT can outweigh

the benefits, for example excessive dosages, excessive treatment delays, or remote survey bias may have a greater effect on results. Ethical issues may also prevent running RCTs for known effective treatments. For more on issues with RCTs see [101,102].



Figure 18. **For COVID-19, observational study results do not systematically differ from RCTs, RR 0.98 [0.92-1.05] across 172 treatments [96].**

Using all studies identifies efficacy 8+ months faster (9+ months for low-cost treatments)

Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. Of these, 58% have been confirmed in RCTs, with a mean delay of 7.7 months (64% with 8.9 months delay for low-cost treatments). The remaining treatments either have no RCTs, or the point estimate is consistent.

Summary

We need to evaluate each trial on its own merits. RCTs for a given medication and disease may be more reliable, however they may also be less reliable. For off-patent medications, very high conflict of interest trials may be more likely to be RCTs, and more likely to be large trials that dominate meta analyses.



Figure 15. **Random effects meta-analysis for all Randomized Controlled Trials.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.



Figure 16. **Random effects meta-analysis for RCT mortality results.**



Figure 17. **Random effects meta-analysis for RCT hospitalization results.**

Exclusions

To avoid bias in the selection of studies, we analyze all non-retracted studies. Here we show the results after excluding studies with major issues likely to alter results, non-standard studies, and studies where very minimal detail is currently available. Our bias evaluation is based on analysis of each study and identifying when there is a significant chance that limitations will substantially change the outcome of the study. We believe this can be more valuable than checklist-based approaches such as Cochrane GRADE, which can be easily influenced by potential bias, may ignore or underemphasize serious issues not captured in the checklists, and may overemphasize issues unlikely to alter outcomes in specific cases (for example certain specifics of randomization with a very large effect size and well-matched baseline characteristics).

The studies excluded are as below. Figure 19 shows a forest plot for random effects meta-analysis of all studies after exclusions.

Hartono, randomization resulted in significant baseline differences that were not adjusted for.

Shehab, unadjusted results with no group details.



Figure 19. **Random effects meta-analysis for all studies after exclusions.** This plot shows pooled effects, see the specific outcome analyses for individual outcomes. Analysis validating pooled outcomes for COVID-19 can be found below. Effect extraction is pre-specified, using the most serious outcome reported. For details see the appendix.

Heterogeneity

Heterogeneity in COVID-19 studies arises from many factors including:

Treatment delay

The time between infection or the onset of symptoms and treatment may critically affect how well a treatment works. For example an antiviral may be very effective when used early but may not be effective in late stage disease, and may even be harmful. Oseltamivir, for example, is generally only considered effective for influenza when used within 0-36 or 0-48 hours [105,106]. Baloxavir marboxil studies for influenza also show that treatment delay is critical — *Ikematsu et al.* report an 86% reduction in cases for post-exposure prophylaxis, *Hayden et al.* show a 33 hour reduction in the time to alleviation of symptoms for treatment within 24 hours and a reduction of 13 hours for treatment within 24-48 hours, and *Kumar et al.* report only 2.5 hours improvement for inpatient treatment.

Treatment delay	Result
Post-exposure prophylaxis	86% fewer cases [107]
<24 hours	-33 hours symptoms [108]
24-48 hours	-13 hours symptoms [108]
Inpatients	-2.5 hours to improvement [109]

Table 4. **Studies of baloxavir marboxil for influenza show that early treatment is more effective.**

Figure 20 shows a mixed-effects meta-regression for efficacy as a function of treatment delay in COVID-19 studies from 172 treatments, showing that efficacy declines rapidly with treatment delay. Early treatment is critical for COVID-19.



Figure 20. **Early treatment is more effective.** Meta-regression showing efficacy as a function of treatment delay in COVID-19 studies from 172 treatments.

Patient demographics

Details of the patient population including age and comorbidities may critically affect how well a treatment works. For example, many COVID-19 studies with relatively young low-comorbidity patients show all patients recovering quickly with or without treatment. In such cases, there is little room for an effective treatment to improve results, for example as in *López-Medina et al.*

SARS-CoV-2 variants

Efficacy may depend critically on the distribution of SARS-CoV-2 variants encountered by patients. Risk varies significantly across variants [111], for example the Gamma variant shows significantly different characteristics [112-115]. Different mechanisms of action may be more or less effective depending on variants, for example the degree to which TMPRSS2 contributes to viral entry can differ across variants [116,117].

Treatment regimen

Effectiveness may depend strongly on the dosage and treatment regimen.

Medication quality

The quality of medications may vary significantly between manufacturers and production batches, which may significantly affect efficacy and safety. *Williams et al.* analyze ivermectin from 11 different sources, showing highly variable antiparasitic efficacy across different manufacturers. *Xu et al.* analyze a treatment from two different manufacturers, showing 9 different impurities, with significantly different concentrations for each manufacturer. Non-prescription supplements may show very wide variations in quality[1,2].

Other treatments

The use of other treatments may significantly affect outcomes, including supplements, other medications, or other interventions such as prone positioning. Treatments may be synergistic[120-136], therefore efficacy may depend strongly on combined treatments.

Effect measured

Across all studies there is a strong association between different outcomes, for example improved recovery is strongly associated with lower mortality. However, efficacy may differ depending on the effect measured, for example a treatment may be more effective against secondary complications and have minimal effect on viral clearance.

Meta analysis

The distribution of studies will alter the outcome of a meta analysis. Consider a simplified example where everything is equal except for the treatment delay, and effectiveness decreases to zero or below with increasing delay. If there are many studies using very late treatment, the outcome may be negative, even though early treatment is very effective. All meta analyses combine heterogeneous studies, varying in population, variants, and potentially all factors above, and therefore may obscure efficacy by including studies where treatment is less effective. Generally, we expect the estimated effect size from meta analysis to be less than that for the optimal case. Looking at all studies is valuable for providing an overview of all research, important to avoid cherry-picking, and informative when a positive result is found despite combining less-optimal situations. However, the resulting estimate does not apply to specific cases such as early treatment in high-risk populations. While we present results for all studies, we also present treatment time and individual outcome analyses, which may be more informative for specific use cases.

Pooled Effects

Pooled effects are no longer required to show efficacy as of May 2021

This section validates the use of pooled effects for COVID-19, which enables earlier detection of efficacy, however pooled effects are no longer required for curcumin as of May 2021. Efficacy is now known based on specific outcomes for all studies and when restricted to RCTs. Efficacy based on specific outcomes was delayed by 2.4 months compared to using pooled outcomes.

Combining studies is required

For COVID-19, delay in clinical results translates into additional death and morbidity, as well as additional economic and societal damage. Combining the results of studies reporting different outcomes is required. There may be no mortality in a trial with low-risk patients, however a reduction in severity or improved viral clearance may translate into lower mortality in a high-risk population. Different studies may report lower severity, improved recovery, and lower mortality, and the significance may be very high when combining the results. *"The studies reported different outcomes"* is not a good reason for disregarding results. Pooling the results of studies reporting different outcomes allows us to use more of the available information. Logically we should, and do, use additional information when evaluating treatments—for example dose-response and treatment delay-response relationships provide additional evidence of efficacy that is considered when reviewing the evidence for a treatment.

Specific outcome and pooled analyses

We present both specific outcome and pooled analyses. In order to combine the results of studies reporting different outcomes we use the most serious outcome reported in each study, based on the thesis that improvement in the most serious outcome provides comparable measures of efficacy for a treatment. A critical advantage of this approach is simplicity and transparency. There are many other ways to combine evidence for different outcomes, along with additional evidence such as dose-response relationships, however these increase complexity.

Ethical and practical issues limit high-risk trials

Trials with high-risk patients may be restricted due to ethics for treatments that are known or expected to be effective, and they increase difficulty for recruiting. Using less severe outcomes as a proxy for more serious outcomes allows faster and safer collection of evidence.

Validating pooled outcome analysis for COVID-19

For many COVID-19 treatments, a reduction in mortality logically follows from a reduction in hospitalization, which follows from a reduction in symptomatic cases, which follows from a reduction in PCR positivity. We can directly test this for COVID-19.

Analysis of the the association between different outcomes across studies from all 172 treatments we cover confirms the validity of pooled outcome analysis for COVID-19. Figure 21 shows that lower hospitalization is very strongly associated with lower mortality ($p < 0.000000000001$). Similarly, Figure 22 shows that improved recovery is very strongly associated with lower mortality ($p < 0.000000000001$). Considering the extremes, *Singh (D) et al.* show an association between viral clearance and hospitalization or death, with $p = 0.003$ after excluding one large outlier from a mutagenic treatment, and based on 44 RCTs including 52,384 patients. Figure 23 shows that improved viral clearance is strongly associated with fewer serious outcomes. The association is very similar to *Singh (D) et al.*, with higher confidence due to the larger number of studies. As with *Singh (D) et al.*, the confidence increases when excluding the outlier treatment, from $p = 0.000000082$ to $p = 0.0000000033$.



Figure 21. **Lower hospitalization is associated with lower mortality, supporting pooled outcome analysis.**



Figure 22. Improved recovery is associated with lower mortality, supporting pooled outcome analysis.



Figure 21. Improved viral clearance is associated with fewer serious outcomes, supporting pooled outcome analysis.

Pooled outcomes identify efficacy 5 months faster (7 months for RCTs)

Currently, 55 of the treatments we analyze show statistically significant efficacy or harm, defined as ≥10% decreased risk or >0% increased risk from ≥3 studies. 88% of these have been confirmed with one or more specific outcomes, with a mean delay of 4.9 months. When restricting to RCTs only, 57% of treatments showing statistically significant efficacy/harm with pooled effects have been confirmed with one or more specific outcomes, with a mean delay of 7.3 months. Figure 24 shows when treatments were found effective during the pandemic. Pooled outcomes often resulted in earlier detection of efficacy.



Figure 24. **The time when studies showed that treatments were effective, defined as statistically significant improvement of ≥10% from ≥3 studies.** Pooled results typically show efficacy earlier than specific outcome results. Results from all studies often shows efficacy much earlier than when restricting to RCTs. Results reflect conditions as used in trials to date, these depend on the population treated, treatment delay, and treatment regimen.

Limitations

Pooled analysis could hide efficacy, for example a treatment that is beneficial for late stage patients but has no effect on viral clearance may show no efficacy if most studies only examine viral clearance. In practice, it is rare for a non-antiviral treatment to report viral clearance and to not report clinical outcomes; and in practice other sources of heterogeneity such as difference in treatment delay is more likely to hide efficacy.

Summary

Analysis validates the use of pooled effects and shows significantly faster detection of efficacy on average. However, as with all meta analyses, it is important to review the different studies included. We also present individual outcome analyses, which may be more informative for specific use cases.

Discussion

Publication bias

Publishing is often biased towards positive results, however evidence suggests that there may be a negative bias for inexpensive treatments for COVID-19. Both negative and positive results are very important for COVID-19, media in many countries prioritizes negative results for inexpensive treatments (inverting the typical incentive for scientists that

value media recognition), and there are many reports of difficulty publishing positive results [138-141]. For curcumin, there is currently not enough data to evaluate publication bias with high confidence.

One method to evaluate bias is to compare prospective vs. retrospective studies. Prospective studies are more likely to be published regardless of the result, while retrospective studies are more likely to exhibit bias. For example, researchers may perform preliminary analysis with minimal effort and the results may influence their decision to continue. Retrospective studies also provide more opportunities for the specifics of data extraction and adjustments to influence results.

Figure 25 shows a scatter plot of results for prospective and retrospective studies. 40% of retrospective studies report a statistically significant positive effect for one or more outcomes, compared to 74% of prospective studies, consistent with a bias toward publishing negative results. The median effect size for retrospective studies is 41% improvement, compared to 58% for prospective studies, suggesting a potential bias towards publishing results showing lower efficacy.



Figure 25. **Prospective vs. retrospective studies. The diamonds show the results of random effects meta-analysis.**

Funnel plot analysis

Funnel plots have traditionally been used for analyzing publication bias. This is invalid for COVID-19 acute treatment trials — the underlying assumptions are invalid, which we can demonstrate with a simple example. Consider a set of hypothetical perfect trials with no bias. Figure 26 plot A shows a funnel plot for a simulation of 80 perfect trials, with random group sizes, and each patient's outcome randomly sampled (10% control event probability, and a 30% effect size for treatment). Analysis shows no asymmetry ($p > 0.05$). In plot B, we add a single typical variation in COVID-19 treatment trials — treatment delay. Consider that efficacy varies from 90% for treatment within 24 hours, reducing to 10% when treatment is delayed 3 days. In plot B, each trial's treatment delay is randomly selected. Analysis now shows highly significant asymmetry, $p < 0.0001$, with six variants of Egger's test all showing $p < 0.05$ [142-149]. Note that these tests fail even though treatment delay is uniformly distributed. In reality treatment delay is more complex — each trial has a different distribution of delays across patients, and the distribution across trials may be biased (e.g., late treatment trials may be more common). Similarly, many other variations in trials may produce asymmetry, including dose, administration, duration of treatment, differences in SOC, comorbidities, age, variants, and bias in design, implementation, analysis, and reporting.



Figure 26. **Example funnel plot analysis for simulated perfect trials.**

Conflicts of interest

Pharmaceutical drug trials often have conflicts of interest whereby sponsors or trial staff have a financial interest in the outcome being positive. Curcumin for COVID-19 lacks this because it is an inexpensive and widely available supplement. In contrast, most COVID-19 curcumin trials have been run by physicians on the front lines with the primary goal of finding the best methods to save human lives and minimize the collateral damage caused by COVID-19. While pharmaceutical companies are careful to run trials under optimal conditions (for example, restricting patients to those most likely to benefit, only including patients that can be treated soon after onset when necessary, and ensuring accurate dosing), not all curcumin trials represent the optimal conditions for efficacy.

Limitations

Summary statistics from meta analysis necessarily lose information. As with all meta analyses, studies are heterogeneous, with differences in treatment delay, treatment regimen, patient demographics, variants, conflicts of interest, standard of care, and other factors. We provide analyses for specific outcomes and by treatment delay, and we aim to identify key characteristics in the forest plots and summaries. Results should be viewed in the context of study characteristics.

Some analyses classify treatment based on early or late administration, as done here, while others distinguish between mild, moderate, and severe cases. Viral load does not indicate degree of symptoms — for example patients may have a high viral load while being asymptomatic. With regard to treatments that have antiviral properties, timing of treatment is critical — late administration may be less helpful regardless of severity.

Details of treatment delay per patient is often not available. For example, a study may treat 90% of patients relatively early, but the events driving the outcome may come from 10% of patients treated very late. Our 5 day cutoff for early treatment may be too conservative, 5 days may be too late in many cases.

Comparison across treatments is confounded by differences in the studies performed, for example dose, variants, and conflicts of interest. Trials with conflicts of interest may use designs better suited to the preferred outcome.

In some cases, the most serious outcome has very few events, resulting in lower confidence results being used in pooled analysis, however the method is simpler and more transparent. This is less critical as the number of studies increases. Restriction to outcomes with sufficient power may be beneficial in pooled analysis and improve accuracy when there are few studies, however we maintain our pre-specified method to avoid any retrospective changes.

Studies show that combinations of treatments can be highly synergistic and may result in many times greater efficacy than individual treatments alone [120-136]. Therefore standard of care may be critical and benefits may diminish or disappear if standard of care does not include certain treatments.

This real-time analysis is constantly updated based on submissions. Accuracy benefits from widespread review and submission of updates and corrections from reviewers. Less popular treatments may receive fewer reviews.

No treatment or intervention is 100% available and effective for all current and future variants. Efficacy may vary significantly with different variants and within different populations. All treatments have potential side effects. Propensity to experience side effects may be predicted in advance by qualified physicians. We do not provide medical advice. Before taking any medication, consult a qualified physician who can compare all options, provide personalized advice, and provide details of risks and benefits based on individual medical history and situations.

Notes

1 of the 28 studies compare against other treatments, which may reduce the effect seen. 10 of 28 studies combine treatments. The results of curcumin alone may differ. 10 of 21 RCTs use combined treatment. 4 other meta analyses show significant improvements with curcumin for mortality [4-7], hospitalization [4,7], recovery [6], and symptoms [4].

Reviews

Many reviews cover curcumin for COVID-19, presenting additional background on mechanisms, formulations, and related results, including [82,150-163].

Other studies

Additional preclinical or review papers suggesting potential benefits of curcumin for COVID-19 include [194-266]. We have not reviewed these studies in detail.

Perspective

Results compared with other treatments

SARS-CoV-2 infection and replication involves a complex interplay of 100+ host and viral proteins and other factors [28-35], providing many therapeutic targets. Over 9,000 compounds have been predicted to reduce COVID-19 risk [36], either by directly minimizing infection or replication, by supporting immune system function, or by minimizing secondary complications. Figure 27 shows an overview of the results for curcumin in the context of multiple COVID-19 treatments, and Figure 28 shows a plot of efficacy vs. cost for COVID-19 treatments.



Figure 27. **Scatter plot showing results within the context of multiple COVID-19 treatments.** Diamonds shows the results of random effects meta-analysis. 0.6% of 9,000+ proposed treatments show efficacy[267].



Figure 28. **Efficacy vs. cost for COVID-19 treatments.**

Conclusion

Curcumin is an effective treatment for COVID-19. Significantly lower risk is seen for mortality, ventilation, hospitalization, progression, recovery, and viral clearance. 19 studies from 17 independent teams in 9 countries show significant benefit. Meta analysis using the most serious outcome reported shows 41% [30-50%] lower risk. Results are similar for Randomized Controlled Trials, higher quality studies, and peer-reviewed studies. Results are very robust — in exclusion sensitivity analysis 27 of 28 studies must be excluded to avoid finding statistically significant efficacy in pooled analysis.

Studies typically use advanced formulations for greatly improved bioavailability.

4 other meta analyses show significant improvements with curcumin for mortality[4-7], hospitalization[4,7], recovery[6], and symptoms[4].

Study Notes

Abbaspour-Aghdam



RCT with 30 nanocurcumin and 30 control patients in Iran, showing lower mortality and improved recovery, without statistical significance, and improved NK cell function. 160mg nanocurcumin for 21 days.

Ahmadi



RCT 60 outpatients in Iran, 30 treated with nano-curcumin showing lower hospitalization and faster recovery with treatment.

Ahmadi



RCT 76 hospitalized patients, showing improved recovery with nanocurcumin. Authors note that pure curcumin is limited due to rapid metabolism, low bio-availability, weak aqueous solubility, and systemic deletion, and that the nanocurcumin formulation used improves curcumin's solubility, stability, half-life, and bioavailability. The dropout rate was higher in the curcumin group, in part due to discontinuation for side effects. Authors do not provide detailed discharge criteria.

Alcântara



Prospective study of 131 mild-moderate COVID-19 patients showing significant reduction in time to symptom relief and complete recovery with pharmaceutical-grade curcumin.

Aldwihi



Retrospective survey-based analysis of 738 COVID-19 patients in Saudi Arabia, showing lower hospitalization with vitamin C, turmeric, zinc, and nigella sativa, and higher hospitalization with vitamin D. For vitamin D, most patients continued prophylactic use. For vitamin C, the majority of patients continued prophylactic use. For nigella sativa, the majority of patients started use during infection. Authors do not specify the fraction of prophylactic use for turmeric and zinc.

Asadirad



RCT 60 hospitalized patients in Iran, 30 treated with nano-curcumin, showing significant improvements in inflammatory cytokines, and improvements in clinical outcomes without statistical significance. 240mg/day nano-curcumin for 7days.

Askari



Small RCT 46 outpatients in Iran, 23 treated with curcimin-piperine, showing no significant difference in recovery. 1000mg curcumin and 10mg piperine/day for 14 days.

Bejan



Retrospective 9,748 COVID-19 patients in the USA showing lower hospitalization with turmeric extract.

Chitre



RCT 208 moderate COVID-19 patients in India, 103 treated with a combination of turmeric, ashwagandha, boswellia, and ginger, showing improved recovery with treatment. The dose of curcumin is unknown and bioavailability may be poor.

Din Ujjan



Small RCT with 50 outpatients, 25 treated with curcumin, quercetin, and vitamin D, showing improved recovery and viral clearance with treatment. 168mg curcumin, 260mg, 360IU vitamin D3 daily for 14 days.

Gérain



RCT 49 hospitalized COVID-19 patients, 25 treated with curcumin and quercetin, shower lower mortality/ICU admission and improved recovery with treatment. All patients received vitamin D.

336mg curcumin, 520mg quercetin, and 18µg vitamin D3 daily for 14 days. The control arm received 20µg vitamin D3 daily. Baseline fever favored treatment while vaccination favored control.

Hartono



RCT with 30 patients treated with curcumin and virgin coconut oil (VCO), and 30 SOC patients in Indonesia, showing faster viral clearance with treatment. Treatment also reduced IL-1β, IL-2, IL-6, IL-18, and IFN-β levels. VCO improves the bioavailability of curcumin. There were large unadjusted differences in baseline severity and age, for example 20% vs. 47% of patients >50. VCO 30ml and curcumin 1g tid for 21 days. 066/UN27.06.6.1/KEPK/EC/2020.

Hassaniazad



Small RCT with 40 low risk patients in Iran, 20 treated with nano-curcumin, showing no significant difference in outcomes with treatment. Authors note that treatment can improve peripheral blood inflammatory indices and modulate immune response by decreasing Th1 and Th17 responses, increasing T regulatory responses, further reducing IL-17 and IFN-γ, and increasing suppressive cytokines TGF-β and IL-4.

Hellou



RCT 50 hospitalized patients in Israel, 33 treated with curcumin, vitamin C, artemisinin, and frankincense oral spray, showing improved recovery with treatment.

Kartika



Retrospective 246 hospitalized patients in Indonesia, 136 treated with curcumin, showing shorter hospitalization time with treatment. All patients received vitamin C, D, and zinc.

Khan



RCT 50 COVID+ outpatients in Pakistan, 25 treated with curcumin, quercetin, and vitamin D, showing significantly faster viral clearance, significantly improved CRP, and faster resolution of acute symptoms (p=0.154). 168mg curcumin, 260mg quercetin and 360IU cholecalciferol.

Kishimoto



RCT 138 COVID-19 outpatients in Japan showing lower progression to fever and hypoxemia with curcuRouge, a highly bioavailable oral curcumin formulation, compared to placebo. The curcuRouge group also had a greater reduction in body temperature and took fewer antipyretic medications. The event rate was lower than expected and the difference in progression was not statistically significant.

Majeed



RCT 100 patients in India, 50 treated with ImmuActive (curcumin, andrographolides, resveratrol, zinc, selenium, and piperine), showing improved recovery with treatment.

Nimer



Survey 2,148 COVID-19 recovered patients in Jordan, showing lower hospitalization with turmeric prophylaxis, not reaching statistical significance.

Pawar



RCT 140 patients, 70 treated with curcumin and piperine (for absorption), and 70 treated with probiotics, showing faster recovery, lower progression, and lower mortality with curcumin.

Saber-Moghaddam



Small prospective nonrandomized trial with 41 patients, 21 treated with curcumin, showing lower disease progression and faster recovery with treatment. IRCT20200408046990N1.

Sadeghizadeh



RCT 42 hospitalized moderate/severe COVID-19 patients in Iran, showing lower progression and improved recovery with nano-curcumin. Nano-curcumin 70mg bid for 14 days.

Sankhe



RCT 174 patients in India, 87 treated with AyurCoro-3 (turmeric, gomutra, potassium alum, khadisakhar, bos indicus milk, ghee), showing faster recovery with treatment. EC/NEW/INST/2019/245.

Sankhe



RCT with 60 hospitalized patients treated with Ayurcov and 60 control patients in India, showing improved viral clearance and faster symptom resolution in the mild/moderate group, but no significant differences in the severe group. Ayurcov contains curcuma longa, go ark, sphatika (alum), sita (rock candy), godugdham (bos indicus) milk, and goghritam (bos indicus ghee).

Shehab



Retrospective survey-based analysis of 349 COVID-19 patients, showing a lower risk of severe cases with vitamin D, zinc, turmeric, and honey prophylaxis in unadjusted analysis, without statistical significance. REC/UG/2020/03.

Tahmasebi



RCT 40 hospitalized, 40 ICU, and 40 control patients in Iran, showing lower mortality and improved regulatory T cell responses with nanocurcumin treatment (SinaCurcumin).

Thomas



RCT 147 long COVID patients in the UK, 56 treated with a phytochemical-rich concentrated food capsule, showing improved recovery with treatment. Treatment included curcumin, bioflavonoids, chamomile, ellagic acid, and resveratrol.

Valizadeh



Small RCT with 40 nano-curcumin patients and 40 control patients showing lower mortality with treatment. Authors conclude that nano-curcumin may be able to modulate the increased rate of inflammatory cytokines especially IL-1β and IL-6 mRNA expression and cytokine secretion in COVID-19 patients, which may improve clinical outcomes.

Appendix 1. Methods and Data

We perform ongoing searches of PubMed, medRxiv, Europe PMC, ClinicalTrials.gov, The Cochrane Library, Google Scholar, Research Square, ScienceDirect, Oxford University Press, the reference lists of other studies and meta-analyses, and submissions to the site c19early.org. Search terms are curcumin and COVID-19 or SARS-CoV-2. Automated searches are performed twice daily, with all matches reviewed for inclusion. All studies regarding the use of curcumin for COVID-19 that report a comparison with a control group are included in the main analysis. Sensitivity analysis is performed, excluding studies with major issues, epidemiological studies, and studies with minimal available information. Studies with major unexplained data issues, for example major outcome data that is impossible to be correct with no response from the authors, are excluded. This is a living analysis and is updated regularly.



Figure 29. **Mid-recovery results can more accurately reflect efficacy when almost all patients recover.** *Mateja et al.* **confirm that intermediate viral load results more accurately reflect hospitalization/death.**

We extracted effect sizes and associated data from all studies. If studies report multiple kinds of effects then the most serious outcome is used in pooled analysis, while other outcomes are included in the outcome specific analyses. For example, if effects for mortality and cases are reported then they are both used in specific outcome analyses, while mortality is used for pooled analysis. If symptomatic results are reported at multiple times, we use the latest time, for example if mortality results are provided at 14 days and 28 days, the results at 28 days have preference. Mortality alone is preferred over combined outcomes. Outcomes with zero events in both arms are not used, the next most serious outcome with one or more events is used. For example, in low-risk populations with no mortality, a reduction in mortality with treatment is not possible, however a reduction in hospitalization, for example, is still valuable. Clinical outcomes are considered more important than viral outcomes. When basically all patients recover in both treatment and control groups, preference for viral clearance and recovery is given to results mid-recovery where available. After most or all patients have recovered there is little or no room for an effective treatment to do better, however faster recovery is valuable. An IPD meta-analysis confirms that intermediate viral load reduction is more closely associated with hospitalization/death than later viral load reduction [268]. If only individual symptom data is available, the most serious symptom has priority, for example difficulty breathing or low SpO_2 is more important than cough. When results provide an odds ratio, we compute the relative risk when possible, or convert to a relative risk according to *Zhang (B) et al.* Reported confidence intervals and *p*-values are used when available, and adjusted values are used when provided. If multiple types of adjustments are reported propensity score matching and multivariable regression has preference over propensity score matching or weighting, which has preference over multivariable regression. Adjusted results have preference over unadjusted results for a more serious outcome when the adjustments significantly alter results. When needed, conversion between reported *p*-values and confidence intervals followed *Altman, Altman (B)*, and Fisher's exact test was used to calculate *p*-values for event data. If continuity correction for zero values is required, we use the reciprocal of the opposite arm with the sum of the correction factors equal to 1 [272]. Results are expressed with RR < 1.0 favoring treatment, and using the risk of a negative outcome when applicable (for example, the risk of death rather than the risk of survival). If studies only report relative continuous values such as relative times, the ratio of the time for the treatment group versus the time for the control group is used. Calculations are done in Python (3.13.5) with scipy (1.16.0), pythonmeta (1.26), numpy (2.3.1), statsmodels (0.14.4), and plotly (6.2.0).

Forest plots are computed using PythonMeta [273] with the DerSimonian and Laird random effects model (the fixed effect assumption is not plausible in this case) and inverse variance weighting. Results are presented with 95% confidence intervals. Heterogeneity among studies was assessed using the I^2 statistic. Mixed-effects meta-regression results are computed with R (4.4.0) using the metafor (4.6-0) and rms (6.8-0) packages, and using the most serious sufficiently powered outcome. For all statistical tests, a *p*-value less than 0.05 was considered statistically significant. Grobid 0.8.2 is used to parse PDF documents.

We have classified studies as early treatment if most patients are not already at a severe stage at the time of treatment (for example based on oxygen status or lung involvement), and treatment started within 5 days of the onset of symptoms. If studies contain a mix of early treatment and late treatment patients, we consider the treatment time of patients contributing most to the events (for example, consider a study where most patients are treated early but late treatment patients are included, and all mortality events were observed with late treatment patients). We note that a shorter time may be preferable. Antivirals are typically only considered effective when used within a shorter timeframe, for example 0-36 or 0-48 hours for oseltamivir, with longer delays not being effective [105,106].

We received no funding, this research is done in our spare time. We have no affiliations with any pharmaceutical companies or political parties.

A summary of study results is below. Please submit updates and corrections at https://c19early.org/tmeta.html.

Early treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Ahmadi, 6/19/2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 11 authors, study period April 2020 - July 2020.	risk of hospitalization, 85.7% lower, RR 0.14, $p = 0.24$, treatment 0 of 30 (0.0%), control 3 of 30 (10.0%), NNT 10.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	recovery time, 20.6% lower, relative time 0.79, $p = 0.37$, treatment 30, control 30.
Alcântara, 6/4/2025, prospective, Brazil, preprint, mean age 44.9, 6 authors, study period 15 March, 2021 - 5 May, 2022, CURCOVID trial.	risk of hospitalization, 37.1% lower, RR 0.63, $p = 0.73$, treatment 3 of 58 (5.2%), control 6 of 73 (8.2%), NNT 33.
	ER visit, 25.9% higher, RR 1.26, $p = 0.78$, treatment 7 of 58 (12.1%), control 7 of 73 (9.6%).
	clinical recovery, 37.1% lower, RR 0.63, $p < 0.001$, treatment mean 7.8 (±6.79) n=58, control mean 12.4 (±5.32) n=73.
	symptom relief, 36.7% lower, RR 0.63, $p < 0.001$, treatment mean 4.2 (±4.01) n=58, control mean 6.64 (±2.46) n=73.
Aldwihi, 5/11/2021, retrospective, Saudi Arabia, peer-reviewed, survey, mean age 36.5, 8 authors, study period August 2020 - October 2020.	risk of hospitalization, 31.2% lower, RR 0.69, $p = 0.10$, treatment 30 of 144 (20.8%), control 207 of 594 (34.8%), NNT 7.1, adjusted per study, odds ratio converted to relative risk, multivariable.
Askari, 6/6/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 11 authors, study period November 2020 - April 2021, trial IRCT20121216011763N46.	risk of no recovery, 26.5% lower, RR 0.74, $p = 0.26$, treatment 13, control 13, all symptoms combined.
	risk of no recovery, 125.0% higher, RR 2.25, $p = 0.58$, treatment 3 of 8 (37.5%), control 1 of 6 (16.7%), dyspnea.
	risk of no recovery, 433.3% higher, RR 5.33, $p = 0.19$, treatment 2 of 6 (33.3%), control 0 of 7 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), ague.
	risk of no recovery, 72.9% lower, RR 0.27, $p = 0.04$, treatment 2 of 12 (16.7%), control 8 of 13 (61.5%), NNT 2.2, weakness.
	risk of no recovery, 40.0% lower, RR 0.60, $p = 0.42$, treatment 3 of 10 (30.0%), control 7 of 14 (50.0%), NNT 5.0, muscular pain.

	risk of no recovery, 38.5% lower, RR 0.62, *p* = 0.65, treatment 4 of 13 (30.8%), control 4 of 8 (50.0%), NNT 5.2, headache.
	risk of no recovery, 71.4% higher, RR 1.71, *p* = 1.00, treatment 2 of 7 (28.6%), control 1 of 6 (16.7%), sore throat.
	risk of no recovery, 12.5% lower, RR 0.88, *p* = 1.00, treatment 1 of 8 (12.5%), control 1 of 7 (14.3%), NNT 56, sputum cough.
	risk of no recovery, no change, RR 1.00, *p* = 1.00, treatment 3 of 13 (23.1%), control 3 of 13 (23.1%), dry cough.
Chitre, 11/23/2022, Double Blind Randomized Controlled Trial, placebo-controlled, India, peer-reviewed, 8 authors, study period September 2020 - April 2021, this trial uses multiple treatments in the treatment arm (combined with ashwagandha, boswellia, ginger) - results of individual treatments may vary, trial CTRI/2020/09/027817.	**recovery time, 11.3% lower, relative time 0.89, *p* = 0.04**, treatment 89, control 86.
	fever, 11.0% lower, RR 0.89, *p* = 0.03, treatment 70 of 89 (78.7%), control 76 of 86 (88.4%), NNT 10, day 4.
	congestion, 20.0% lower, RR 0.80, *p* = 0.05, treatment 89, control 86, mid-recovery, day 7.
	sore throat, 20.0% lower, RR 0.80, *p* = 0.09, treatment 89, control 86, mid-recovery, day 7.
	cough, 14.3% lower, RR 0.86, *p* = 0.14, treatment 89, control 86, mid-recovery, day 7.
	dyspnea, 15.4% lower, RR 0.85, *p* = 0.15, treatment 89, control 86, mid-recovery, day 7.
	pain, 8.3% lower, RR 0.92, *p* = 0.41, treatment 89, control 86, mid-recovery, day 7.
	fatigue, 16.7% lower, RR 0.83, *p* = 0.13, treatment 89, control 86, mid-recovery, day 7.
	headache, 16.7% lower, RR 0.83, *p* = 0.12, treatment 89, control 86, mid-recovery, day 7.
	chills, 18.2% lower, RR 0.82, *p* = 0.09, treatment 89, control 86, mid-recovery, day 7.
	diarrhea, 25.0% lower, RR 0.75, *p* = 0.08, treatment 89, control 86, mid-recovery, day 7.
	vomiting, 18.2% lower, RR 0.82, *p* = 0.07, treatment 89, control 86, mid-recovery, day 7.
	smell, 16.7% lower, RR 0.83, *p* = 0.06, treatment 89, control 86, mid-recovery, day 7.
	taste, 16.7% lower, RR 0.83, *p* = 0.14, treatment 89, control 86, mid-recovery, day 7.
Din Ujjan, 1/18/2023, Randomized Controlled Trial, Pakistan, peer-reviewed, 6 authors, study period 21 September, 2021 - 21 January, 2022, this trial uses multiple treatments in the treatment arm (combined with quercetin and vitamin D) - results of individual treatments may vary, trial NCT04603690 (history).	**risk of no recovery, 28.6% lower, RR 0.71, *p* = 0.11**, treatment 15 of 25 (60.0%), control 21 of 25 (84.0%), NNT 4.2, no symptoms, day 7.
	risk of no recovery, 71.4% lower, RR 0.29, *p* < 0.001, treatment 6 of 25 (24.0%), control 21 of 25 (84.0%), NNT 1.7, <= 1 symptom, day 7.

	risk of no recovery, 76.9% lower, RR 0.23, p = 0.005, treatment 3 of 25 (12.0%), control 13 of 25 (52.0%), NNT 2.5, <= 2 symptoms, day 7.
	risk of no recovery, 85.7% lower, RR 0.14, p = 0.23, treatment 0 of 25 (0.0%), control 3 of 25 (12.0%), NNT 8.3, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), <= 3 symptoms, day 7.
	risk of no viral clearance, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14.
	risk of no viral clearance, 73.7% lower, RR 0.26, p < 0.001, treatment 5 of 25 (20.0%), control 19 of 25 (76.0%), NNT 1.8, day 7.
Khan, 5/1/2022, Randomized Controlled Trial, Pakistan, peer-reviewed, 7 authors, study period 2 September, 2021 - 28 November, 2021, this trial uses multiple treatments in the treatment arm (combined with quercetin and vitamin D) - results of individual treatments may vary, trial NCT05130671 (history).	**risk of no recovery, 33.3% lower, RR 0.67, p = 0.15**, treatment 10 of 25 (40.0%), control 15 of 25 (60.0%), NNT 5.0.
	relative CRP reduction, 39.1% better, RR 0.61, p = 0.006, treatment 25, control 25.
	risk of no viral clearance, 50.0% lower, RR 0.50, p = 0.009, treatment 10 of 25 (40.0%), control 20 of 25 (80.0%), NNT 2.5.
Kishimoto, 6/24/2024, Double Blind Randomized Controlled Trial, placebo-controlled, Japan, peer-reviewed, 15 authors, study period February 2022 - January 2023, trial jRCTs051210176.	**SpO_2<96 or temperature≥37.5, 46.8% lower, HR 0.53, p = 0.48**, treatment 2 of 71 (2.8%), control 4 of 67 (6.0%), NNT 32, Cox proportional hazards.
Majeed, 10/11/2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 4 authors, study period September 2020 - November 2020, this trial uses multiple treatments in the treatment arm (combined with andrographolides, resveratrol, zinc, selenium, and piperine) - results of individual treatments may vary, trial CTRI/2020/09/027841.	**risk of mechanical ventilation, 66.2% lower, RR 0.34, p = 1.00**, treatment 0 of 45 (0.0%), control 1 of 47 (2.1%), NNT 47, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of hospitalization, 79.7% lower, RR 0.20, p = 0.49, treatment 0 of 45 (0.0%), control 2 of 47 (4.3%), NNT 24, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	relative ordinal scale, 43.0% better, RR 0.57, p = 0.004, treatment 45, control 47, day 28.
	risk of no recovery, 24.6% lower, RR 0.75, p = 0.08, treatment 26 of 45 (57.8%), control 36 of 47 (76.6%), NNT 5.3, day 28.
	time to viral-, 5.8% lower, relative time 0.94, p = 0.47, treatment 45, control 47.
Pawar, 5/28/2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 8 authors, study period July 2020 - September 2020, this trial compares with another treatment - results may be better when compared to placebo, trial CTRI/2020/05/025482.	**risk of death, 81.8% lower, RR 0.18, p = 0.02**, treatment 2 of 70 (2.9%), control 11 of 70 (15.7%), NNT 7.8.
	risk of death, 60.0% lower, RR 0.40, p = 0.39, treatment 2 of 15 (13.3%), control 5 of 15 (33.3%), NNT 5.0, severe group.
	risk of death, 90.9% lower, RR 0.09, p = 0.05, treatment 0 of 25 (0.0%), control 5 of 25 (20.0%), NNT 5.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate group.

	risk of death, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), mild group.
Saber-Moghaddam, 1/3/2021, prospective, Iran, peer-reviewed, 9 authors.	risk of progression, 94.3% lower, RR 0.06, p = 0.001, treatment 0 of 21 (0.0%), control 8 of 20 (40.0%), NNT 2.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of no recovery, 38.4% lower, RR 0.62, p = 0.04, treatment 11 of 21 (52.4%), control 17 of 20 (85.0%), NNT 3.1.
	hospitalization time, 44.8% lower, relative time 0.55, p < 0.001, treatment 21, control 20.
Sankhe, 8/10/2021, Randomized Controlled Trial, India, peer-reviewed, 8 authors, study period October 2020 - March 2021, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary.	risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 87 (0.0%), control 4 of 87 (4.6%), NNT 22, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of mechanical ventilation, 75.0% lower, RR 0.25, p = 0.37, treatment 1 of 87 (1.1%), control 4 of 87 (4.6%), NNT 29.
	risk of no 2-point improvement, 46.5% lower, RR 0.54, p = 0.002, treatment 29 of 87 (33.3%), control 60 of 87 (69.0%), NNT 2.8, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, day 7 mid-recovery.
	hospitalization time, 10.0% lower, relative time 0.90, p = 0.40, treatment 87, control 87.

Late treatment

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Abbaspour-Aghdam, 9/17/2022, Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 16 authors, trial IRCT20200324046851N1.	risk of death, 71.4% lower, RR 0.29, p = 0.15, treatment 2 of 30 (6.7%), control 7 of 30 (23.3%), NNT 6.0.
	risk of no recovery, 86.3% lower, RR 0.14, p = 0.04, treatment 1 of 28 (3.6%), control 6 of 23 (26.1%), NNT 4.4, dyspnea.
	risk of no recovery, 89.9% lower, RR 0.10, p = 0.04, treatment 0 of 28 (0.0%), control 4 of 23 (17.4%), NNT 5.8, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), fever >39.0.
	risk of no recovery, 38.4% lower, RR 0.62, p = 0.17, treatment 9 of 28 (32.1%), control 12 of 23 (52.2%), NNT 5.0, bilateral chest radiograph involvement.
	risk of no recovery, 58.9% lower, RR 0.41, p = 0.27, treatment 3 of 28 (10.7%), control 6 of 23 (26.1%), NNT 6.5, cough.
	risk of no recovery, 81.6% lower, RR 0.18, p = 0.20, treatment 0 of 28 (0.0%), control 2 of 23 (8.7%), NNT 12, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), headache.

Ahmadi (B), 7/28/2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 5 authors, study period December 2021 - March 2022, trial IRCT20211126053183N1.	**risk of oxygen therapy, 58.0% lower, RR 0.42, $p = 0.06$**, treatment 5 of 29 (17.2%), control 16 of 39 (41.0%), NNT 4.2.
	relative improvement in SpO_2, 67.2% better, RR 0.33, $p = 0.04$, treatment mean 3.32 (±3.84) n=29, control mean 1.09 (±4.71) n=39.
	risk of no recovery, 49.6% lower, RR 0.50, $p = 0.33$, treatment 3 of 29 (10.3%), control 8 of 39 (20.5%), NNT 9.8, chest pain.
	risk of no recovery, 34.5% higher, RR 1.34, $p = 1.00$, treatment 1 of 29 (3.4%), control 1 of 39 (2.6%), chills.
	risk of no recovery, 58.0% lower, RR 0.42, $p = 0.06$, treatment 5 of 29 (17.2%), control 16 of 39 (41.0%), NNT 4.2, cough.
	risk of no recovery, 77.7% lower, RR 0.22, $p = 0.50$, treatment 0 of 29 (0.0%), control 2 of 39 (5.1%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), sore throat.
	risk of no recovery, 63.8% lower, RR 0.36, $p < 0.001$, treatment 7 of 29 (24.1%), control 26 of 39 (66.7%), NNT 2.4, fatigue.
	risk of no recovery, 91.3% lower, RR 0.09, $p = 0.03$, treatment 0 of 29 (0.0%), control 6 of 39 (15.4%), NNT 6.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), myalgia.
	risk of no recovery, 8.9% higher, RR 1.09, $p = 0.81$, treatment 17 of 29 (58.6%), control 21 of 39 (53.8%), anosmia.
	risk of no recovery, 10.3% lower, RR 0.90, $p = 1.00$, treatment 8 of 29 (27.6%), control 12 of 39 (30.8%), NNT 31, ageusia.
	risk of no recovery, 10.3% lower, RR 0.90, $p = 1.00$, treatment 2 of 29 (6.9%), control 3 of 39 (7.7%), NNT 126, anorexia.
	risk of no recovery, 63.6% lower, RR 0.36, $p = 1.00$, treatment 0 of 29 (0.0%), control 1 of 39 (2.6%), NNT 39, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), diarrhea.
	risk of no recovery, 234.5% higher, RR 3.34, $p = 0.43$, treatment 1 of 29 (3.4%), control 0 of 39 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), nausea.
Asadirad, 1/17/2022, Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 7 authors, study period June 2020 - July 2020.	**risk of death, 25.9% lower, RR 0.74, $p = 0.74$**, treatment 5 of 27 (18.5%), control 6 of 24 (25.0%), NNT 15, excluding patients that stopped treatment due to progression - 3 for curcumin and 6 for control.
	risk of progression, 50.0% lower, RR 0.50, $p = 0.47$, treatment 3 of 30 (10.0%), control 6 of 30 (20.0%), NNT 10.0.
	risk of unresolved fever, 45.3% lower, RR 0.55, $p = 0.09$, treatment 8 of 27 (29.6%), control 13 of 24 (54.2%), NNT 4.1.
	risk of unresolved dyspnea, 28.9% lower, RR 0.71, $p = 0.72$, treatment 4 of 27 (14.8%), control 5 of 24 (20.8%), NNT 17.
	risk of unresolved cough, 40.7% lower, RR 0.59, $p = 0.36$, treatment 6 of 27 (22.2%), control 9 of 24 (37.5%), NNT 6.5.

	risk of O2 <92%, 36.5% lower, RR 0.63, *p* = 0.51, treatment 5 of 27 (18.5%), control 7 of 24 (29.2%), NNT 9.4.
	risk of O2 <97%, 20.0% lower, RR 0.80, *p* = 0.21, treatment 18 of 27 (66.7%), control 20 of 24 (83.3%), NNT 6.0.
Gérain, 6/22/2023, Randomized Controlled Trial, Belgium, peer-reviewed, 8 authors, study period 1 April, 2021 - 29 October, 2021, this trial uses multiple treatments in the treatment arm (combined with quercetin) - results of individual treatments may vary, trial NCT04844658 (history).	**risk of death, 67.1% lower, RR 0.33, *p* = 0.49**, treatment 0 of 25 (0.0%), control 1 of 24 (4.2%), NNT 24, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7.
	risk of death/ICU, 91.1% lower, RR 0.09, *p* = 0.02, treatment 0 of 25 (0.0%), control 5 of 24 (20.8%), NNT 4.8, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7.
	risk of mechanical ventilation, 89.1% lower, RR 0.11, *p* = 0.05, treatment 0 of 25 (0.0%), control 4 of 24 (16.7%), NNT 6.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7.
	risk of ICU admission, 89.1% lower, RR 0.11, *p* = 0.05, treatment 0 of 25 (0.0%), control 4 of 24 (16.7%), NNT 6.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 7.
	risk of no hospital discharge, 72.6% lower, RR 0.27, *p* = 0.07, treatment 2 of 25 (8.0%), control 7 of 24 (29.2%), NNT 4.7, day 14.
	risk of no hospital discharge, 58.9% lower, RR 0.41, *p* = 0.02, treatment 6 of 25 (24.0%), control 14 of 24 (58.3%), NNT 2.9, day 7.
	hospitalization time, 37.5% lower, relative time 0.62, *p* = 0.008, treatment median 5.0 IQR 4.0 n=25, control median 8.0 IQR 6.0 n=24.
	relative WHO score, 50.0% better, RR 0.50, *p* = 0.04, treatment 22, control 24, day 7.
Hartono, 2/22/2022, Randomized Controlled Trial, Indonesia, peer-reviewed, 13 authors, study period May 2020 - September 2020, this trial uses multiple treatments in the treatment arm (combined with virgin coconut oil) - results of individual treatments may vary, excluded in exclusion analyses: randomization resulted in significant baseline differences that were not adjusted for.	**risk of no viral clearance, 53.3% lower, RR 0.47, *p* < 0.001**, treatment 14 of 30 (46.7%), control 30 of 30 (100.0%), NNT 1.9, day 10.
	risk of no viral clearance, 75.0% lower, RR 0.25, *p* = 0.002, treatment 4 of 30 (13.3%), control 16 of 30 (53.3%), NNT 2.5, day 14.
	risk of no viral clearance, 66.7% lower, RR 0.33, *p* = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 21.
Hassaniazad, 9/19/2021, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors.	**relative improvement in SpO_2, 45.7% worse, RR 1.46, *p* = 0.90**, treatment 20, control 20.
Hellou, 5/19/2022, Double Blind Randomized Controlled Trial, placebo-controlled, Israel, peer-reviewed, 6 authors, study period 8 May, 2020 - 21 December, 2020, this trial uses multiple treatments	**relative NEWS2 score, 76.7% better, RR 0.23, *p* = 0.04**, treatment mean 0.52 (±0.67) n=33, control mean 2.23 (±3.2) n=17, day 15.

in the treatment arm (combined with vitamin C, artemisinin, and frankincense) - results of individual treatments may vary, trial NCT04382040 (history).	risk of oxygen therapy, 92.2% lower, RR 0.08, p = 0.01, treatment 0 of 33 (0.0%), control 4 of 17 (23.5%), NNT 4.2, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 15.
	oxygen time, 69.7% lower, relative time 0.30, p = 0.17, treatment mean 2.3 (±1.4) n=33, control mean 7.6 (±4.6) n=17.
	hospitalization time, 13.3% lower, relative time 0.87, p = 0.92, treatment mean 7.8 (±7.3) n=33, control mean 9.0 (±8.0) n=17.
	risk of no viral clearance, 9.8% lower, RR 0.90, p = 0.77, treatment 14 of 33 (42.4%), control 8 of 17 (47.1%), NNT 22, day 15.
Kartika, 1/28/2022, retrospective, Indonesia, preprint, 6 authors, study period January 2021 - June 2021.	**hospitalization time, 41.0% lower, relative time 0.59, p = 0.048**, treatment 139, control 107.
Sadeghizadeh, 4/29/2023, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors, trial IRCT20170128032241N3.	**risk of progression, 92.3% lower, RR 0.08, p = 0.02**, treatment 0 of 21 (0.0%), control 6 of 21 (28.6%), NNT 3.5, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	hospitalization time, 24.5% lower, relative time 0.75, p = 0.007, treatment mean 7.7 (±2.3) n=21, control mean 10.2 (±3.3) n=21.
	relative chest CT score, 67.5% better, RR 0.33, p < 0.001, treatment mean 1.3 (±0.82) n=21, control mean 4.0 (±1.8) n=21, day 14.
	risk of no recovery, 66.7% lower, RR 0.33, p = 0.61, treatment 1 of 21 (4.8%), control 3 of 21 (14.3%), NNT 10, day 14, dyspnea/oxygen need.
	risk of no recovery, 80.0% lower, RR 0.20, p = 0.18, treatment 1 of 21 (4.8%), control 5 of 21 (23.8%), NNT 5.2, day 14, fever.
	risk of no recovery, 85.7% lower, RR 0.14, p = 0.04, treatment 1 of 21 (4.8%), control 7 of 21 (33.3%), NNT 3.5, day 14, cough.
	risk of no recovery, 80.0% lower, RR 0.20, p = 0.49, treatment 0 of 21 (0.0%), control 2 of 21 (9.5%), NNT 10, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, headache.
	risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, fatigue.
	risk of no recovery, 75.0% lower, RR 0.25, p = 0.34, treatment 1 of 21 (4.8%), control 4 of 21 (19.0%), NNT 7.0, day 14, myalgia.
	risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 14, diarrhea.
	risk of no recovery, 50.0% lower, RR 0.50, p = 1.00, treatment 1 of 21 (4.8%), control 2 of 21 (9.5%), NNT 21, day 14, inappetence.
	risk of no recovery, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 21 (0.0%), control 1 of 21 (4.8%), NNT 21, relative risk is not 0 because of continuity correction due to zero events (with

	reciprocal of the contrasting arm), day 14, nausea.
Sankhe (B), 3/25/2022, Single Blind Randomized Controlled Trial, India, peer-reviewed, 10 authors, study period June 2020 - November 2020, this trial uses multiple treatments in the treatment arm (combined with gomutra, potassium alum, khadisakhar, bos indicus milk, ghee) - results of individual treatments may vary.	risk of death, 85.7% lower, RR 0.14, $p = 0.24$, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of mechanical ventilation, 85.7% lower, RR 0.14, $p = 0.24$, treatment 0 of 60 (0.0%), control 3 of 60 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
	risk of ICU admission, 66.7% lower, RR 0.33, $p = 0.62$, treatment 1 of 60 (1.7%), control 3 of 60 (5.0%), NNT 30.
	hospitalization time, 10.0% lower, relative time 0.90, $p = 0.40$, treatment 45, control 45, moderate group.
	hospitalization time, 16.7% lower, relative time 0.83, $p = 0.20$, treatment 15, control 15, severe group.
	recovery time, 31.9% lower, relative time 0.68, $p < 0.001$, treatment 45, control 45, moderate group, fever.
	recovery time, 36.1% lower, relative time 0.64, $p < 0.001$, treatment 45, control 45, moderate group, dyspnea.
	recovery time, 4.3% lower, relative time 0.96, $p = 0.74$, treatment 15, control 15, severe group, fever.
	recovery time, 4.8% higher, relative time 1.05, $p = 0.10$, treatment 15, control 15, severe group, dyspnea.
	relative Ct increase, 44.4% better, RR 0.56, $p = 0.003$, treatment mean 9.98 (±6.39) n=44, control mean 5.55 (±6.91) n=43, moderate group.
Tahmasebi, 3/28/2021, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 14 authors.	risk of death, 83.3% lower, RR 0.17, $p = 0.11$, treatment 1 of 40 (2.5%), control 6 of 40 (15.0%), NNT 8.0.
	risk of death, 66.7% lower, RR 0.33, $p = 1.00$, treatment 0 of 20 (0.0%), control 1 of 20 (5.0%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), non-ICU patients.
	risk of death, 80.0% lower, RR 0.20, $p = 0.18$, treatment 1 of 20 (5.0%), control 5 of 20 (25.0%), NNT 5.0, ICU patients.
Thomas, 3/22/2022, Double Blind Randomized Controlled Trial, placebo-controlled, United Kingdom, peer-reviewed, 7 authors, study period May 2020 - May 2021, this trial uses multiple treatments in the treatment arm (combined with bioflavonoids, chamomile, ellagic acid, resveratrol) - results of individual treatments may vary, Phyto-V trial.	relative improvement, 44.3% better, RR 0.56, $p = 0.02$, treatment mean 6.1 (±7.5) n=74, control mean 3.4 (±6.1) n=73, CFS.
	relative improvement, 81.8% better, RR 0.18, $p < 0.001$, treatment mean 6.6 (±10.5) n=74, control mean 1.2 (±7.4) n=73, SWS.
	relative improvement, 63.6% better, RR 0.36, $p = 0.02$, treatment mean 1.1 (±2.0) n=74, control mean 0.4 (±1.5) n=73, CSS.
Valizadeh, 10/20/2020, Double Blind Randomized Controlled Trial, Iran, peer-reviewed, 12 authors.	risk of death, 50.0% lower, RR 0.50, $p = 0.30$, treatment 4 of 20 (20.0%), control 8 of 20 (40.0%), NNT 5.0.

Prophylaxis

Effect extraction follows pre-specified rules as detailed above and gives priority to more serious outcomes. For pooled analyses, the first (most serious) outcome is used, which may differ from the effect a paper focuses on. Other outcomes are used in outcome specific analyses.

Bejan, 2/28/2021, retrospective, USA, peer-reviewed, mean age 42.0, 6 authors.	risk of hospitalization, 59.0% lower, OR 0.41, $p = 0.048$, treatment 148, control 9,600, adjusted per study, RR approximated with OR.
Nimer, 6/10/2022, retrospective, Jordan, peer-reviewed, survey, mean age 40.2, 4 authors, study period March 2021 - July 2021.	risk of hospitalization, 30.8% lower, RR 0.69, $p = 0.08$, treatment 29 of 329 (8.8%), control 179 of 1,819 (9.8%), adjusted per study, odds ratio converted to relative risk, multivariable.
	risk of severe case, 12.6% lower, RR 0.87, $p = 0.47$, treatment 40 of 329 (12.2%), control 211 of 1,819 (11.6%), adjusted per study, odds ratio converted to relative risk, multivariable.
Shehab, 2/28/2022, retrospective, multiple countries, peer-reviewed, survey, 7 authors, study period September 2020 - March 2021, excluded in exclusion analyses: unadjusted results with no group details.	risk of severe case, 42.4% lower, RR 0.58, $p = 0.55$, treatment 2 of 32 (6.2%), control 24 of 221 (10.9%), NNT 22, unadjusted, severe vs. mild cases.

Supplementary Data

Supplementary Data

Footnotes

a. Viral infection and replication involves attachment, entry, uncoating and release, genome replication and transcription, translation and protein processing, assembly and budding, and release. Each step can be disrupted by therapeutics.

b. The trimeric spike (S) protein is a glycoprotein that mediates viral entry by binding to the host ACE2 receptor, is critical for SARS-CoV-2's ability to infect host cells, and is a target of neutralizing antibodies. Inhibition of the spike protein prevents viral attachment, halting infection at the earliest stage.

c. The receptor binding domain is a specific region of the spike protein that binds ACE2 and is a major target of neutralizing antibodies. Focusing on the precise binding site allows highly specific disruption of viral attachment with reduced potential for off-target effects.

d. The main protease or M^{pro}, also known as $3CL^{pro}$ or nsp5, is a cysteine protease that cleaves viral polyproteins into functional units needed for replication. Inhibiting M^{pro} disrupts the SARS-CoV-2 lifecycle within the host cell, preventing the creation of new copies.

e. RNA-dependent RNA polymerase (RdRp), also called nsp12, is the core enzyme of the viral replicase-transcriptase complex that copies the positive-sense viral RNA genome into negative-sense templates for progeny RNA synthesis. Inhibiting RdRp blocks viral genome replication and transcription.

f. The papain-like protease (PLpro) has multiple functions including cleaving viral polyproteins and suppressing the host immune response by deubiquitination and deISGylation of host proteins. Inhibiting PLpro may block viral replication and help restore normal immune responses.

g. The angiotensin converting enzyme 2 (ACE2) protein is a host cell transmembrane protein that serves as the cellular receptor for the SARS-CoV-2 spike protein. ACE2 is expressed on many cell types, including epithelial cells in the lungs, and allows the virus to enter and infect host cells. Inhibition may affect ACE2's physiological function in blood pressure control.

h. The nucleocapsid (N) protein binds and encapsulates the viral genome by coating the viral RNA. N enables formation and release of infectious virions and plays additional roles in viral replication and pathogenesis. N is also an immunodominant antigen used in diagnostic assays.

i. Non-structural protein 10 (nsp10) serves as an RNA chaperone and stabilizes conformations of nsp12 and nsp14 in the replicase-transcriptase complex, which synthesizes new viral RNAs. Nsp10 disruption may destabilize replicase-transcriptase complex activity.

j. The helicase, or nsp13, protein unwinds the double-stranded viral RNA, a crucial step in replication and transcription. Inhibition may prevent viral genome replication and the creation of new virus components.

k. The interaction between the SARS-CoV-2 spike protein and the human ACE2 receptor is a primary method of viral entry, inhibiting this interaction can prevent the virus from attaching to and entering host cells, halting infection at an early stage.

l. Transmembrane protease serine 2 (TMPRSS2) is a host cell protease that primes the spike protein, facilitating cellular entry. TMPRSS2 activity helps enable cleavage of the spike protein required for membrane fusion and virus entry. Inhibition may especially protect respiratory epithelial cells, buy may have physiological effects.

m. Calu-3 is a human lung adenocarcinoma cell line with moderate ACE2 and TMPRSS2 expression and SARS-CoV-2 susceptibility. It provides a model of the human respiratory epithelium, but many not be ideal for modeling early stages of infection due to the moderate expression levels of ACE2 and TMPRSS2.

n. A549 is a human lung carcinoma cell line with low ACE2 expression and SARS-CoV-2 susceptibility. Viral entry/replication can be studied but the cells may not replicate all aspects of lung infection.

o. 293T is a human embryonic kidney cell line that can be engineered for high ACE2 expression and SARS-CoV-2 susceptibility. 293T cells are easily transfected and support high protein expression.

p. HEK293-hACE2 is a human embryonic kidney cell line with high ACE2 expression and SARS-CoV-2 susceptibility. Cells have been transfected with a plasmid to express the human ACE2 (hACE2) protein.

q. 293T/hACE2/TMPRSS2 is a human embryonic kidney cell line engineered for high ACE2 and TMPRSS2 expression, which mimics key aspects of human infection. 293T/hACE2/TMPRSS2 cells are very susceptible to SARS-CoV-2 infection.

r. Vero E6 is an African green monkey kidney cell line with low/no ACE2 expression and high SARS-CoV-2 susceptibility. The cell line is easy to maintain and supports robust viral replication, however the monkey origin may not accurately represent human responses.

s. SH-SY5Y is a human neuroblastoma cell line that exhibits neuronal phenotypes. It is commonly used as an in vitro model for studying neurotoxicity, neurodegenerative diseases, and neuronal differentiation.

References

1. **Crawford** et al., *Analysis of Select Dietary Supplement Products Marketed to Support or Boost the Immune System*, JAMA Network Open, doi:10.1001/jamanetworkopen.2022.26040.
2. **Crighton** et al., *Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health*, Journal of Pharmaceutical and Biomedical Analysis, doi:10.1016/j.jpba.2019.112834.
3. **Chanyandura** et al., *Evaluation of The Pharmaceutical Quality of the Most Commonly Purchased Vitamin C (Ascorbic Acid) Formulations in COVID-19 Infection in South Africa*, J. Basic Appl. Pharm. Sci., doi:10.33790/jbaps1100105.
4. **Vahedian-Azimi** et al., *Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials*, Nutrients, doi:10.3390/nu14020256.
5. **Kow** et al., *The effect of curcumin on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials*, Phytotherapy Research, doi:10.1002/ptr.7468.
6. **Shafiee** et al., *Curcumin for the treatment of COVID-19 patients: A meta-analysis of randomized controlled trials*, Phytotherapy Research, doi:10.1002/ptr.7724.
7. **Shojaei** et al., *The effectiveness of nano-curcumin on patients with COVID-19: A systematic review of clinical trials*, Phytotherapy Research, doi:10.1002/ptr.7778.
8. **Ryu** et al., *Fibrin drives thromboinflammation and neuropathology in COVID-19*, Nature, doi:10.1038/s41586-024-07873-4.
9. **Rong** et al., *Persistence of spike protein at the skull-meninges-brain axis may contribute to the neurological sequelae of COVID-19*, Cell Host & Microbe, doi:10.1016/j.chom.2024.11.007.
10. **Yang** et al., *SARS-CoV-2 infection causes dopaminergic neuron senescence*, Cell Stem Cell, doi:10.1016/j.stem.2023.12.012.
11. **Scardua-Silva** et al., *Microstructural brain abnormalities, fatigue, and cognitive dysfunction after mild COVID-19*, Scientific Reports, doi:10.1038/s41598-024-52005-7.

12. **Hampshire** et al., *Cognition and Memory after Covid-19 in a Large Community Sample*, New England Journal of Medicine, doi:10.1056/NEJMoa2311330.
13. **Duloquin** et al., *Is COVID-19 Infection a Multiorganic Disease? Focus on Extrapulmonary Involvement of SARS-CoV-2*, Journal of Clinical Medicine, doi:10.3390/jcm13051397.
14. **Sodagar** et al., *Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches*, Biomolecules, doi:10.3390/biom12070971.
15. **Sagar** et al., *COVID-19-associated cerebral microbleeds in the general population*, Brain Communications, doi:10.1093/braincomms/fcae127.
16. **Verma** et al., *Persistent Neurological Deficits in Mouse PASC Reveal Antiviral Drug Limitations*, bioRxiv, doi:10.1101/2024.06.02.596989.
17. **Panagea** et al., *Neurocognitive Impairment in Long COVID: A Systematic Review*, Archives of Clinical Neuropsychology, doi:10.1093/arclin/acae042.
18. **Ariza** et al., *COVID-19: Unveiling the Neuropsychiatric Maze—From Acute to Long-Term Manifestations*, Biomedicines, doi:10.3390/biomedicines12061147.
19. **Vashisht** et al., *Neurological Complications of COVID-19: Unraveling the Pathophysiological Underpinnings and Therapeutic Implications*, Viruses, doi:10.3390/v16081183.
20. **Ahmad** et al., *Neurological Complications and Outcomes in Critically Ill Patients With COVID-19: Results From International Neurological Study Group From the COVID-19 Critical Care Consortium*, The Neurohospitalist, doi:10.1177/19418744241292487.
21. **Wang** et al., *SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction*, Translational Neurodegeneration, doi:10.1186/s40035-024-00458-1.
22. **Eberhardt** et al., *SARS-CoV-2 infection triggers pro-atherogenic inflammatory responses in human coronary vessels*, Nature Cardiovascular Research, doi:10.1038/s44161-023-00336-5.
23. **Van Tin** et al., *Spike Protein of SARS-CoV-2 Activates Cardiac Fibrogenesis through NLRP3 Inflammasomes and NF-κB Signaling*, Cells, doi:10.3390/cells13161331.
24. **Borka Balas** et al., *COVID-19 and Cardiac Implications—Still a Mystery in Clinical Practice*, Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm2405125.
25. **AlTaweel** et al., *An In-Depth Insight into Clinical, Cellular and Molecular Factors in COVID19-Associated Cardiovascular Ailments for Identifying Novel Disease Biomarkers, Drug Targets and Clinical Management Strategies*, Archives of Microbiology & Immunology, doi:10.26502/ami.936500177.
26. **Saha** et al., *COVID-19 beyond the lungs: Unraveling its vascular impact and cardiovascular complications—mechanisms and therapeutic implications*, Science Progress, doi:10.1177/00368504251322069.
27. **Trender** et al., *Changes in memory and cognition during the SARS-CoV-2 human challenge study*, eClinicalMedicine, doi:10.1016/j.eclinm.2024.102842.
28. **Dugied** et al., *Multimodal SARS-CoV-2 interactome sketches the virus-host spatial organization*, Communications Biology, doi:10.1038/s42003-025-07933-z.
29. **Malone** et al., *Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design*, Nature Reviews Molecular Cell Biology, doi:10.1038/s41580-021-00432-z.
30. **Murigneux** et al., *Proteomic analysis of SARS-CoV-2 particles unveils a key role of G3BP proteins in viral assembly*, Nature Communications, doi:10.1038/s41467-024-44958-0.
31. **Lv** et al., *Host proviral and antiviral factors for SARS-CoV-2*, Virus Genes, doi:10.1007/s11262-021-01869-2.
32. **Lui** et al., *Nsp1 facilitates SARS-CoV-2 replication through calcineurin-NFAT signaling*, Virology, doi:10.1128/mbio.00392-24.
33. **Niarakis** et al., *Drug-target identification in COVID-19 disease mechanisms using computational systems biology approaches*, Frontiers in Immunology, doi:10.3389/fimmu.2023.1282859.
34. **Katiyar** et al., *SARS-CoV-2 Assembly: Gaining Infectivity and Beyond*, Viruses, doi:10.3390/v16111648.
35. **Wu** et al., *Decoding the genome of SARS-CoV-2: a pathway to drug development through translation inhibition*, RNA Biology, doi:10.1080/15476286.2024.2433830.
36. **c19early.org**, c19early.org/treatments.html.
37. **Nag** et al., *Curcumin inhibits spike protein of new SARS-CoV-2 variant of concern (VOC) Omicron, an in silico study*, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2022.105552.
38. **Moschovou** et al., *Exploring the Binding Effects of Natural Products and Antihypertensive Drugs on SARS-CoV-2: An In Silico Investigation of Main Protease and Spike Protein*, International Journal of Molecular Sciences, doi:10.3390/ijms242115894.
39. **Kandeil** et al., *Bioactive Polyphenolic Compounds Showing Strong Antiviral Activities against Severe Acute Respiratory Syndrome Coronavirus 2*, Pathogens, doi:10.3390/pathogens10060758.
40. **Singh** et al., *Computational studies to analyze effect of curcumin inhibition on coronavirus D614G mutated spike protein*, The Seybold Report, doi:10.17605/OSF.IO/TKEXJ.
41. **Boseila** et al., *Throat spray formulated with virucidal Pharmaceutical excipients as an effective early prophylactic or treatment strategy against pharyngitis post-exposure to SARS CoV-2*, European Journal of Pharmaceutics and Biopharmaceutics, doi:10.1016/j.ejpb.2024.114279.
42. **Haque** et al., *Exploring potential therapeutic candidates against COVID-19: a molecular docking study*, Discover Molecules, doi:10.1007/s44345-024-00005-5.
43. **Al balawi** et al., *Assessing multi-target antiviral and antioxidant activities of natural compounds against SARS-CoV-2: an integrated in vitro and in silico study*, Bioresources and Bioprocessing, doi:10.1186/s40643-024-00822-z.
44. **Kant** et al., *Structure-based drug discovery to identify SARS-CoV2 spike protein–ACE2 interaction inhibitors*, Journal of Biomolecular Structure and Dynamics,

doi:10.1080/07391102.2023.2300060.

45. **Srivastava** et al., *Paradigm of Well-Orchestrated Pharmacokinetic Properties of Curcuminoids Relative to Conventional Drugs for the Inactivation of SARS-CoV-2 Receptors: An In Silico Approach*, Stresses, doi:10.3390/stresses3030043.

46. **Eleraky** et al., *Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2*, International Journal of Nanomedicine, doi:10.2147/IJN.S423251.

47. **Rajamanickam** et al., *Exploring the Potential of Siddha Formulation MilagaiKudineer-Derived Phytotherapeutics Against SARS-CoV-2: An In-Silico Investigation for Antiviral Intervention*, Journal of Pharmacy and Pharmacology Research, doi:10.26502/fjppr.0105.

48. **Naderi Beni** et al., *In silico studies of anti-oxidative and hot temperament-based phytochemicals as natural inhibitors of SARS-CoV-2 Mpro*, PLOS ONE, doi:10.1371/journal.pone.0295014.

49. **Rajagopal** et al., *Activity of phytochemical constituents of Curcuma longa (turmeric) and Andrographis paniculata against coronavirus (COVID-19): an in silico approach*, Future Journal of Pharmaceutical Sciences, doi:10.1186/s43094-020-00126-x.

50. **Rampogu** et al., *Molecular Docking and Molecular Dynamics Simulations Discover Curcumin Analogue as a Plausible Dual Inhibitor for SARS-CoV-2*, International Journal of Molecular Sciences, doi:10.3390/ijms23031771.

51. **Sekiou** et al., *In-Silico Identification of Potent Inhibitors of COVID-19 Main Protease (Mpro) and Angiotensin Converting Enzyme 2 (ACE2) from Natural Products: Quercetin, Hispidulin, and Cirsimaritin Exhibited Better Potential Inhibition than Hydroxy-Chloroquine Against COVID-19 Main Protease Active Site and ACE2*, ChemRxiv, doi:10.26434/chemrxiv.12181404.v1.

52. **Singh (B)** et al., *Unlocking the potential of phytochemicals in inhibiting SARS-CoV-2 M Pro protein - An in-silico and cell-based approach*, Research Square, doi:10.21203/rs.3.rs-3888947/v1.

53. **Winih Kinasih** et al., *Analisis in silico interaksi senyawa kurkuminoid terhadap enzim main protease 6LU7 dari SARS-CoV-2*, Duta Pharma Journal, doi:10.47701/djp.v3i1.2904.

54. **Thapa** et al., *In-silico Approach for Predicting the Inhibitory Effect of Home Remedies on Severe Acute Respiratory Syndrome Coronavirus-2*, Makara Journal of Science, doi:10.7454/mss.v27i3.1609.

55. **Bahun** et al., *Inhibition of the SARS-CoV-2 3CLpro main protease by plant polyphenols*, Food Chemistry, doi:10.1016/j.foodchem.2021.131594.

56. **Singh (C)** et al., *Potential of turmeric-derived compounds against RNA-dependent RNA polymerase of SARS-CoV-2: An in-silico approach*, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.104965.

57. **Alkafaas** et al., *A study on the effect of natural products against the transmission of B.1.1.529 Omicron*, Virology Journal, doi:10.1186/s12985-023-02160-6.

58. **Hidayah** et al., *Bioinformatics study of curcumin, demethoxycurcumin, bisdemethoxycurcumin and cyclocurcumin compounds in Curcuma longa as an antiviral agent via nucleocapsid on SARS-CoV-2 inhibition*, International Conference on Organic and Applied Chemistry, doi:10.1063/5.0197724.

59. **Suravajhala** et al., *Comparative Docking Studies on Curcumin with COVID-19 Proteins*, Preprints, doi:10.20944/preprints202005.0439.v3.

60. **Li** et al., *Thermal shift assay (TSA)-based drug screening strategy for rapid discovery of inhibitors against the Nsp13 helicase of SARS-CoV-2*, Animals and Zoonoses, doi:10.1016/j.azn.2024.06.001.

61. **Najimi** et al., *Phytochemical Inhibitors of SARS-CoV-2 Entry: Targeting the ACE2-RBD Interaction with l-Tartaric Acid, l-Ascorbic Acid, and Curcuma longa Extract*, ChemistrySelect, doi:10.1002/slct.202406035.

62. **Mohd Abd Razak** et al., *In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds*, Natural Product Communications, doi:10.1177/1934578X231188861.

63. **Goc** et al., *Phenolic compounds disrupt spike-mediated receptor-binding and entry of SARS-CoV-2 pseudo-virions*, PLOS ONE, doi:10.1371/journal.pone.0253489.

64. **Guijarro-Real** et al., *Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity*, Foods, doi:10.3390/foods10071503.

65. **Wu (B)** et al., *Potential Mechanism of Curcumin and Resveratrol against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-2780614/v1.

66. **Emam** et al., *Establishment of in-house assay for screening of anti-SARS-CoV-2 protein inhibitors*, AMB Express, doi:10.1186/s13568-024-01739-8.

67. **Bormann** et al., *Turmeric Root and Its Bioactive Ingredient Curcumin Effectively Neutralize SARS-CoV-2 In Vitro*, Viruses, doi:10.3390/v13101914.

68. **Zhang** et al., *Computational Discovery of Mitochondrial Dysfunction Biomarkers in Severe SARS-CoV-2 Infection: Facilitating Pytomedicine Screening*, Phytomedicine, doi:10.1016/j.phymed.2024.155784.

69. **Nittayananta** et al., *A novel film spray containing curcumin inhibits SARS-CoV-2 and influenza virus infection and enhances mucosal immunity*, Virology Journal, doi:10.1186/s12985-023-02282-x.

70. **Septisetyani** et al., *Curcumin and turmeric extract inhibited SARS-CoV-2 pseudovirus cell entry and Spike mediated cell fusion*, bioRxiv, doi:10.1101/2023.09.28.560070.

71. **Leka** et al., *In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds*, Phytotherapy Research, doi:10.1002/ptr.7463.

72. **Teshima** et al., *Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells*, Natural Product Research, doi:10.1080/14786419.2023.2194647.

73. **Marín-Palma** et al., *Curcumin Inhibits In Vitro SARS-CoV-2 Infection In Vero E6 Cells through Multiple Antiviral Mechanisms*, Molecules, doi:10.3390/molecules26226900.

74. **Nicoliche** et al., *Antiviral, anti-inflammatory and antioxidant effects of curcumin and curcuminoids in SH-SY5Y cells infected by SARS-CoV-2*, Scientific Reports, doi:10.1038/s41598-024-61662-7.

75. **Fam** et al., *Channel activity of SARS-CoV-2 viroporin ORF3a inhibited by adamantanes and phenolic plant metabolites*, Scientific Reports, doi:10.1038/s41598-023-31764-9.

76. **Patel** et al., *Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV*, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1868338.

77. **Jena** et al., *Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies*, Scientific Reports, doi:10.1038/s41598-021-81462-7.

78. **Sahebkar** et al., *Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials*, Pharmacological Research, doi:10.1016/j.phrs.2016.03.026.

79. **Derosa** et al., *Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials*, Pharmacological Research, doi:10.1016/j.phrs.2016.07.004.

80. **Daily** et al., *Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials*, Journal of Medicinal Food, doi:10.1089/jmf.2016.3705.

81. **Gupta** et al., *Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials*, The AAPS Journal, doi:10.1208/s12248-012-9432-8.

82. **Rattis** et al., *Curcumin as a Potential Treatment for COVID-19*, Frontiers in Pharmacology, doi:10.3389/fphar.2021.675287.

83. **Öztürkkan** et al., *In Silico investigation of the effects of curcuminoids on the spike protein of the omicron variant of SARS-CoV-2*, Baku State University Journal of Chemistry and Material Sciences, 1:2, bsuj.bsu.edu.az/uploads/pdf/ec4204d62f7802de54e6092bf7860029.pdf.

84. **Yunze** et al., *Therapeutic effect and potential mechanism of curcumin, an active ingredient in Tongnao Decoction, on COVID-19 combined with stroke: a network pharmacology study and GEO database mining*, Research Square, doi:10.21203/rs.3.rs-4329762/v1.

85. **Agamah** et al., *Network-based multi-omics-disease-drug associations reveal drug repurposing candidates for COVID-19 disease phases*, ScienceOpen, doi:10.58647/DRUGARXIV.PR000010.v1.

86. **Olubiyi** et al., *Novel dietary herbal preparations with inhibitory activities against multiple SARS-CoV-2 targets: A multidisciplinary investigation into antiviral activities*, Food Chemistry Advances, doi:10.1016/j.focha.2025.100969.

87. **Kamble** et al., *Nanoparticulate curcumin spray imparts prophylactic and therapeutic properties against SARS-CoV-2*, Emergent Materials, doi:10.1007/s42247-024-00754-6.

88. **Goc (B)** et al., *Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants*, European Journal of Microbiology and Immunology, doi:10.1556/1886.2021.00022.

89. **Vaiss** et al., *Curcumin and quercetin co-encapsulated in nanoemulsions for nasal administration: a promising therapeutic and prophylactic treatment for viral respiratory infections*, European Journal of Pharmaceutical Sciences, doi:10.1016/j.ejps.2024.106766.

90. **Panda** et al., *The enhanced bioavailability of free curcumin and bioactive-metabolite tetrahydrocurcumin from a dispersible, oleoresin-based turmeric formulation*, Medicine, doi:10.1097/MD.0000000000026601.

91. **Zeraatkar** et al., *Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review*, BMJ Medicine, doi:10.1136/bmjmed-2022-0003091.

92. **Davidson** et al., *No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study*, Journal of Clinical Epidemiology, doi:10.1016/j.jclinepi.2023.08.011.

93. **Jadad** et al., *Randomized Controlled Trials: Questions, Answers, and Musings, Second Edition*, doi:10.1002/9780470691922.

94. **Gøtzsche**, P., *Bias in double-blind trials*, Doctoral Thesis, University of Copenhagen, www.scientificfreedom.dk/2023/05/16/bias-in-double-blind-trials-doctoral-thesis/.

95. **Als-Nielsen** et al., *Association of Funding and Conclusions in Randomized Drug Trials*, JAMA, doi:10.1001/jama.290.7.921.

96. **c19early.org (B)**, c19early.org/tsupp.html#fig_rctobs.

97. **Concato** et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507.

98. **Anglemyer** et al., *Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials*, Cochrane Database of Systematic Reviews 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2.

99. **c19early.org (C)**, c19early.org/rctobs.html.

100. **Lee** et al., *Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines*, Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482.

101. **Deaton** et al., *Understanding and misunderstanding randomized controlled trials*, Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005.

102. **Nichol** et al., *Challenging issues in randomised controlled trials*, Injury, 2010, doi: 10.1016/j.injury.2010.03.033, www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.

103. **Hartono** et al., *The Effect of Curcumin and Virgin Coconut Oil Towards Cytokines Levels in COVID-19 Patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia*, Pharmacognosy Journal, doi:10.5530/pj.2022.14.27.

104. **Shehab** et al., *Immune-boosting effect of natural remedies and supplements on progress of, and recovery from COVID-19 infection*, Tropical Journal of Pharmaceutical Research, doi:10.4314/tjpr.v21i2.13.

105. **Treanor** et al., *Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial*, JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016.

106. **McLean** et al., *Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial*, Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100.

107. **Ikematsu** et al., *Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts*, New England Journal of Medicine, doi:10.1056/NEJMoa1915341.

108. **Hayden** et al., *Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents*, New England Journal of Medicine, doi:10.1056/NEJMoa1716197.

109. **Kumar** et al., *Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial*, The Lancet Infectious Diseases, doi:10.1016/S1473-3099(21)00469-2.

110. **López-Medina** et al., *Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial*, JAMA, doi:10.1001/jama.2021.3071.

111. **Korves** et al., *SARS-CoV-2 Genetic Variants and Patient Factors Associated with Hospitalization Risk*, medRxiv, doi:10.1101/2024.03.08.24303818.

112. **Faria** et al., *Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil*, Science, doi:10.1126/science.abh2644.

113. **Nonaka** et al., *SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil, February 2021*, International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.08.003.

114. **Karita** et al., *Trajectory of viral load in a prospective population-based cohort with incident SARS-CoV-2 G614 infection*, medRxiv, doi:10.1101/2021.08.27.21262754.

115. **Zavascki** et al., *Advanced ventilatory support and mortality in hospitalized patients with COVID-19 caused by Gamma (P.1) variant of concern compared to other lineages: cohort study at a reference center in Brazil*, Research Square, doi:10.21203/rs.3.rs-910467/v1.

116. **Willett** et al., *The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism*, medRxiv, doi:10.1101/2022.01.03.21268111.

117. **Peacock** et al., *The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry*, bioRxiv, doi:10.1101/2021.12.31.474653.

118. **Williams**, T., *Not All Ivermectin Is Created Equal: Comparing The Quality of 11 Different Ivermectin Sources*, Do Your Own Research, doyourownresearch.substack.com/p/not-all-ivermectin-is-created-equal.

119. **Xu** et al., *A study of impurities in the repurposed COVID-19 drug hydroxychloroquine sulfate by UHPLC-Q/TOF-MS and LC-SPE-NMR*, Rapid Communications in Mass Spectrometry, doi:10.1002/rcm.9358.

120. **Jitobaom** et al., *Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2*, Research Square, doi:10.21203/rs.3.rs-941811/v1.

121. **Jitobaom (B)** et al., *Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations*, BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8.

122. **Jeffreys** et al., *Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2*, International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542.

123. **Ostrov** et al., *Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells*, Pathogens, doi:10.3390/pathogens10111514.

124. **Alsaidi** et al., *Griffithsin and Carrageenan Combination Results in Antiviral Synergy against SARS-CoV-1 and 2 in a Pseudoviral Model*, Marine Drugs, doi:10.3390/md19080418.

125. **Andreani** et al., *In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect*, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.

126. **De Forni** et al., *Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients*, PLoS ONE, doi:10.1371/journal.pone.0276751.

127. **Wan** et al., *Synergistic inhibition effects of andrographolide and baicalin on coronavirus mechanisms by downregulation of ACE2 protein level*, Scientific Reports, doi:10.1038/s41598-024-54722-5.

128. **Said** et al., *The effect of Nigella sativa and vitamin D3 supplementation on the clinical outcome in COVID-19 patients: A randomized controlled clinical trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.1011522.

129. **Fiaschi** et al., *In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants*, Viruses, doi:10.3390/v16020168.

130. **Xing** et al., *Published anti-SARS-CoV-2 in vitro hits share common mechanisms of action that synergize with antivirals*, Briefings in Bioinformatics, doi:10.1093/bib/bbab249.

131. **Chen** et al., *Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir*, ACS Pharmacology & Translational Science, doi:10.1021/acsptsci.1c00022.

132. **Hempel** et al., *Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular*

properties, Chemical Science, doi:10.1039/D1SC01494C.

133. **Schultz** et al., *Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2*, Nature, doi:10.1038/s41586-022-04482-x.

134. **Ohashi** et al., *Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment*, iScience, doi:10.1016/j.isci.2021.102367.

135. **Al Krad** et al., *The protease inhibitor Nirmatrelvir synergizes with inhibitors of GRP78 to suppress SARS-CoV-2 replication*, bioRxiv, doi:10.1101/2025.03.09.642200.

136. **Thairu** et al., *A Comparison of Ivermectin and Non Ivermectin Based Regimen for COVID-19 in Abuja: Effects on Virus Clearance, Days-to-discharge and Mortality*, Journal of Pharmaceutical Research International, doi:10.9734/jpri/2022/v34i44A36328.

137. **Singh (D)** et al., *The relationship between viral clearance rates and disease progression in early symptomatic COVID-19: a systematic review and meta-regression analysis*, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkae045.

138. **Meneguesso**, A., *Médica defende tratamento precoce da Covid-19*, www.youtube.com/watch?v=X5FCrIm_19U.

139. **Boulware**, D., *Comments regarding paper rejection*, twitter.com/boulware_dr/status/1311331372884205570.

140. **Meeus**, G., *Online Comment*, twitter.com/gertmeeus_MD/status/1386636373889781761.

141. **twitter.com**, twitter.com/KashPrime/status/1768487878454124914.

142. **Rothstein**, H., *Publication Bias in Meta-Analysis: Prevention, Assessment and Adjustments*, www.wiley.com/en-ae/Publication+Bias+in+Meta+Analysis:+Prevention,+Assessment+and+Adjustments-p-9780470870143.

143. **Stanley** et al., *Meta-regression approximations to reduce publication selection bias*, Research Synthesis Methods, doi:10.1002/jrsm.1095.

144. **Rücker** et al., *Arcsine test for publication bias in meta-analyses with binary outcomes*, Statistics in Medicine, doi:10.1002/sim.2971.

145. **Peters**, J., *Comparison of Two Methods to Detect Publication Bias in Meta-analysis*, JAMA, doi:10.1001/jama.295.6.676.

146. **Moreno** et al., *Assessment of regression-based methods to adjust for publication bias through a comprehensive simulation study*, BMC Medical Research Methodology, doi:10.1186/1471-2288-9-2.

147. **Macaskill** et al., *A comparison of methods to detect publication bias in meta-analysis*, Statistics in Medicine, doi:10.1002/sim.698.

148. **Egger** et al., *Bias in meta-analysis detected by a simple, graphical test*, BMJ, doi:10.1136/bmj.315.7109.629.

149. **Harbord** et al., *A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints*, Statistics in Medicine, doi:10.1002/sim.2380.

150. **Sanduzzi Zamparelli** et al., *Immune-Boosting and Antiviral Effects of Antioxidants in COVID-19 Pneumonia: A Therapeutic Perspective*, Life, doi:10.3390/life15010113.

151. **Duan** et al., *Bioactive compounds,quercetin, curcumin and β-glucan,regulate innate immunity via the gut-liver-brain axis*, Trends in Food Science & Technology, doi:10.1016/j.tifs.2024.104864.

152. **Rajak** et al., *Antiallergic Implications of Curcumin During COVID-19: Current Status and Perspectives*, Biotechnology of Medicinal Plants with Antiallergy Properties, doi:10.1007/978-981-97-1467-4_4.

153. **Kali** et al., *Curcumin as a Promising Therapy for COVID-19: A Review*, Global Journal of Medical, Pharmaceutical, and Biomedical Update, doi:10.25259/GJMPBU_78_2023.

154. **Vajdi** et al., *Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy*, Pharmacological Reports, doi:10.1007/s43440-024-00585-6.

155. **Yong** et al., *Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases*, International Journal of Nanomedicine, doi:10.2147/ijn.s451206.

156. **Halma** et al., *Exploring autophagy in treating SARS-CoV-2 spike protein-related pathology*, Endocrine and Metabolic Science, doi:10.1016/j.endmts.2024.100163.

157. **Arab** et al., *Immunoregulatory effects of nanocurcumin in inflammatory milieu: Focus on COVID-19*, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2024.116131.

158. **Daskou** et al., *The Role of the NRF2 Pathway in the Pathogenesis of Viral Respiratory Infections*, Pathogens, doi:10.3390/pathogens13010039.

159. **Law** et al., *Photodynamic Action of Curcumin and Methylene Blue against Bacteria and SARS-CoV-2—A Review*, Pharmaceuticals, doi:10.3390/ph17010034.

160. **Donzelli**, A., *Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review*, MDPI AG, doi:10.20944/preprints202312.1178.v1.

161. **Hulscher** et al., *Clinical Approach to Post-acute Sequelae After COVID-19 Infection and Vaccination*, Cureus, doi:10.7759/cureus.49204.

162. **Hegde** et al., *Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?*, ACS Omega, doi:10.1021/acsomega.2c07326.

163. **Kritis** et al., *The combination of bromelain and curcumin as an immune-boosting nutraceutical in the prevention of severe COVID-19*, Metabolism Open, doi:10.1016/j.metop.2020.100066.

164. **Alcântara** et al., *Earlier clinical improvement in mild-moderate acute COVID patients treated with pharmacological-grade Curcumin*, Authorea Inc., doi:10.22541/au.174904567.74543434/v1.

165. **Kishimoto** et al., *Efficacy of highly bioavailable oral curcumin in asymptomatic or mild COVID-19 patients: a double-blind, randomized, placebo-controlled trial*, Journal of Health, Population and Nutrition, doi:10.1186/s41043-024-00584-6.

166. **Bhardwaj** et al., *Effectiveness of ayurvedic formulation, NAOQ19 along with standard care in the treatment of mild-moderate COVID-19 patients: A double blind, randomized, placebo-controlled, multicentric trial*, Journal of Ayurveda and Integrative Medicine, doi:10.1016/j.jaim.2023.100778.

167. **Din Ujjan** et al., *The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial*, Frontiers in Nutrition, doi:10.3389/fnut.2022.1023997.

168. **Chitre** et al., *Phase III randomized clinical trial of BV-4051, an Ayurvedic polyherbal formulation in moderate SARS-CoV-2 infections and its impact on inflammatory biomarkers*, Phytotherapy Research, doi:10.1002/ptr.7683.

169. **Askari** et al., *The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial*, Trials, doi:10.1186/s13063-022-06375-w.

170. **Khan** et al., *Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19—Results From a Pilot Open-Label, Randomized Controlled Trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2022.898062.

171. **Bhardwaja** et al., *An integrative approach to clinical recovery for COVID-19 patients using an Ayurvedic formulation: A multicentric double-blind randomized control trial*, Research Square, doi:10.21203/rs.3.rs-1165680/v1.

172. **Majeed** et al., *A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of a Nutritional Supplement (ImmuActive) for COVID-19 Patients*, Evidence-Based Complementary and Alternative Medicine, doi:10.1155/2021/8447545.

173. **Sankhe** et al., *A prospective, multi center, single blind, randomized controlled study evaluating "AyurCoro3" as an adjuvant in the treatment of mild to moderate COVID*, Journal of Ayurveda and Integrated Medical Sciences, doi:10.21760/jaims.6.4.6.

174. **Ahmadi** et al., *Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial*, Food Science and Nutrition, doi:10.1002/fsn3.2226.

175. **Pawar** et al., *Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial*, Frontiers in Pharmacology, doi:10.3389/fphar.2021.669362.

176. **Aldwihi** et al., *Patients' Behavior Regarding Dietary or Herbal Supplements before and during COVID-19 in Saudi Arabia*, International Journal of Environmental Research and Public Health, doi:10.3390/ijerph18105086.

177. **Saber-Moghaddam** et al., *Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial*, Phytotherapy Research, doi:10.1002/ptr.7004 , doi:10.1002/ptr.7004.

178. **Dound** et al., *A Randomized, Comparative Clinical Study to Evaluate the Activity of CurvicTM Formulation for Management of SARS-COV-2 Infection (COVID-19)*, Journal of Clinical Trials, S3:004, www.longdom.org/open-access/a-randomized-comparative-clinical-study-to-evaluate-the-activity-of-cureqovitaatm-formulation-for-management-of-sarscov2-infection-59374.html.

179. **Ahmadi (B)** et al., *Efficacy of Nanocurcumin as an Add-On Treatment for Patients Hospitalized with COVID-19: A Double-Blind, Randomized Clinical Trial*, International Journal of Clinical Practice, doi:10.1155/2023/5734675.

180. **Gérain** et al., *NASAFYTOL® supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial*, Frontiers in Nutrition, doi:10.3389/fnut.2023.1137407.

181. **Sadeghizadeh** et al., *Promising clinical outcomes of nano-curcumin treatment as an adjunct therapy in hospitalized COVID-19 patients: A randomized, double-blinded, placebo-controlled trial*, Phytotherapy Research, doi:10.1002/ptr.7844.

182. **Abbaspour-Aghdam** et al., *Immunomodulatory role of Nanocurcumin in COVID-19 patients with dropped natural killer cells frequency and function*, European Journal of Pharmacology, doi:10.1016/j.ejphar.2022.175267.

183. **Hellou** et al., *Effect of ArtemiC in patients with COVID-19: A Phase II prospective study*, Journal of Cellular and Molecular Medicine, doi:10.1111/jcmm.17337.

184. **Sankhe (B)** et al., *A Randomized, Controlled, Blinded, Parallel Group, Clinical Trial to study the role of Ayurcov (AyurCoro3), one day regimen as an adjuvant therapy for COVID-19 disease management, at dedicated Covid Hospital (DCH) in India*, Complementary Therapies in Medicine, doi:10.1016/j.ctim.2022.102824.

185. **Thomas** et al., *A Randomised, Double-Blind, Placebo-Controlled Trial Evaluating Concentrated Phytochemical-Rich Nutritional Capsule in Addition to a Probiotic Capsule on Clinical Outcomes among Individuals with COVID-19—The UK Phyto-V Study*, COVID, doi:10.3390/covid2040031.

186. **Kartika** et al., *Curcumin as adjuvant Therapy in Mild - Moderate Covid 19*, ICE on IMERI, 2021, web.archive.org/web/20220209083251/http://writingcenter.fk.ui.ac.id/index.php/p/article/view/40.

187. **Asadirad** et al., *Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial*, Phytotherapy Research, doi:10.1002/ptr.7375.

188. **Honarkar Shafie** et al., *Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial*, Phytotherapy Research, doi:10.1002/ptr.7374.

189. **Hassaniazad** et al., *A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients*, Phytotherapy Research, doi:10.1002/ptr.7294.

190. **Tahmasebi** et al., *Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2*, Life Sciences, doi:10.1016/j.lfs.2021.119437.

191. **Valizadeh** et al., *Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients*, Int. Immunopharmacol., doi:10.1016/j.intimp.2020.107088.

192. **Nimer** et al., *Effect of natural products use prior to infection with COVID-19 on disease severity and hospitalization: A self-reported cross-sectional survey study*, F1000Research, doi:10.12688/f1000research.121933.1.

193. **Bejan** et al., *DrugWAS: Drug-wide Association Studies for COVID-19 Drug Repurposing*, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.2376.

194. **Liu** et al., *Curcumin as an antiviral agent and immune-inflammatory modulator in COVID-19: A scientometric analysis*, Heliyon, doi:10.1016/j.heliyon.2023.e21648.

195. **Hasan** et al., *Potential medicinal plants used in the treatment of COVID-19: a review*, Vegetable crops of Russia, doi:10.18619/2072-9146-2025-2-61-69.

196. **Song** et al., *Natural products for targeting SARS-CoV-2 enzymes, RNA-dependent RNA polymerase and main protease*, Journal of Applied Biological Chemistry, doi:10.3839/jabc.2025.022.

197. **Ma** et al., *Advances in acute respiratory distress syndrome: focusing on heterogeneity, pathophysiology, and therapeutic strategies*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-025-02127-9.

198. **Atatreh** et al., *Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds*, Journal of Enzyme Inhibition and Medicinal Chemistry, doi:10.1080/14756366.2025.2460045.

199. **Kumar (B)** et al., *Advancements in the development of antivirals against SARS-Coronavirus*, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2025.1520811.

200. **Hanai**, T., *COVID-19, Infection Inhibitors and Medicines*, MDPI AG, doi:10.20944/preprints202501.1042.v1.

201. **Motyl** et al., *SARS-CoV-2 Infection and Alpha-Synucleinopathies: Potential Links and Underlying Mechanisms*, International Journal of Molecular Sciences, doi:10.3390/ijms252212079.

202. **Smail** et al., *Decoding the intricacies: a comprehensive analysis of microRNAs in the pathogenesis, diagnosis, prognosis and therapeutic strategies for COVID-19*, Frontiers in Medicine, doi:10.3389/fmed.2024.1430974.

203. **Chatatikun** et al., *Potential of traditional medicines in alleviating COVID-19 symptoms*, Frontiers in Pharmacology, doi:10.3389/fphar.2024.1452616.

204. **Alagawani** et al., *In Silico Development of SARS-CoV-2 Non-covalent Mpro Inhibitors: A Review*, MDPI AG, doi:10.20944/preprints202409.0073.v1.

205. **Jabeen** et al., *Insights for Future Pharmacology: Exploring Phytochemicals as Potential Inhibitors Targeting SARS-CoV-2 Papain-like Protease*, Future Pharmacology, doi:10.3390/futurepharmacol4030029.

206. **Al Adem** et al., *3-chymotrypsin-like protease in SARS-CoV-2*, Bioscience Reports, doi:10.1042/BSR20231395.

207. **Shanmugam** et al., *Targeting SARS-CoV-2 Spike and Main protease with phytochemicals from Herbs and spices: Molecular Docking and dynamics simulation studies.*, Journal of Physics: Conference Series, doi:10.1088/1742-6596/2801/1/012013.

208. **Sharma** et al., *Role of Natural Products against the Spread of SARS-CoV-2 by Inhibition of ACE-2 Receptor: A Review*, Current Pharmaceutical Design, doi:10.2174/0113816128320161240703092622.

209. **Yu** et al., *Cytokine Storm in COVID-19: Insight into Pathological Mechanisms and Therapeutic Benefits of Chinese Herbal Medicines*, Medicines, doi:10.3390/medicines11070014.

210. **Sathishkumar**, K., *From nature to medicine: bioactive compounds in the battle against SARS-CoV-2*, Natural Product Research, doi:10.1080/14786419.2024.2375754.

211. **Lei** et al., *Small molecules in the treatment of COVID-19*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-022-01249-8.

212. **Al-Jamal** et al., *Treating COVID-19 with Medicinal Plants: Is It Even Conceivable? A Comprehensive Review*, Viruses, doi:10.3390/v16030320.

213. **Loucera** et al., *Drug repurposing for COVID-19 using machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection*, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-020-00417-y.

214. **Jamal**, Q., *Antiviral Potential of Plants against COVID-19 during Outbreaks—An Update*, International Journal of Molecular Sciences, doi:10.3390/ijms232113564.

215. **Szabó** et al., *Natural products as a source of Coronavirus entry inhibitors*, Frontiers in Cellular and Infection Microbiology, doi:10.3389/fcimb.2024.1353971.

216. **Sharun** et al., *A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19*, Narra J, doi:10.52225/narra.v2i3.92.

217. **Behboudi** et al., *SARS-CoV-2 mechanisms of cell tropism in various organs considering host factors*, Heliyon, doi:10.1016/j.heliyon.2024.e26577.

218. **Bizzoca** et al., *Natural compounds may contribute in preventing SARS-CoV-2 infection: a narrative review*, Food Science and Human Wellness, doi:10.1016/j.fshw.2022.04.005.

219. **Ramezani** et al., *Effect of herbal compounds on inhibition of coronavirus; A systematic review and meta-analysis*, Authorea, Inc., doi:10.22541/au.170668000.04030360/v1.

220. **Abubakar** et al., *Potential benefits and challenges on the use of phytochemicals for obese COVID-19 patients: A review*, Phytomedicine Plus, doi:10.1016/j.phyplu.2024.100526.

221. **Wang (B)** et al., *Recent advances in chemometric modelling of inhibitors against SARS-CoV-2*, Heliyon, doi:10.1016/j.heliyon.2024.e24209.

222. **Liu (B)** et al., *Plant-derived compounds as potential leads for new drug development targeting COVID-19*, Phytotherapy Research, doi:10.1002/ptr.8105.

223. **Mittal** et al., *Identification of potential molecules against COVID-19 main protease through structure-guided virtual screening approach*, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2020.1768151.

224. **Velásquez** et al., *Effectiveness of Drug Repurposing and Natural Products Against SARS-CoV-2: A Comprehensive Review*, Clinical Pharmacology: Advances and Applications, doi:10.2147/CPAA.S429064.

225. **Khaledi** et al., *A Comprehensive Review of Herbal Recommendations with the Potential to Inhibit COVID-19 Infection*, Journal of Medical Bacteriology, doi:10.18502/jmb.v11i5-6.14362.

226. **Shahali** et al., *A Comprehensive Review on Potentially Therapeutic Agents against COVID-19 from Natural Sources*, Current Traditional Medicine, doi:10.2174/2215083809666230203142343.

227. **Singh (E)** et al., *Computational Approaches to Designing Antiviral Drugs against COVID-19: A Comprehensive Review*, Current Pharmaceutical Design, doi:10.2174/0113816128259795231023193419.

228. **Singh (F)** et al., *Medicinal plants, phytoconstituents and traditional formulation as potential therapies for SARS-CoV-2: a review update*, Vegetos, doi:10.1007/s42535-023-00706-1.

229. **He** et al., *Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets*, Pharmaceutical Biology, doi:10.1080/13880209.2023.2241518.

230. **Khan (B)** et al., *Possible therapeutic targets for SARS-CoV-2 infection and COVID-19*, Journal of Allergy & Infectious Diseases, doi:10.46439/allergy.2.028.

231. **Mushebenge** et al., *Assessing the Potential Contribution of in Silico Studies in Discovering Drug Candidates that Interact with Various SARS-CoV-2 Receptors*, MDPI AG, doi:10.20944/preprints202308.0434.v1.

232. **Onyango**, O., *In Silico Models for Anti-COVID-19 Drug Discovery: A Systematic Review*, Advances in Pharmacological and Pharmaceutical Sciences, doi:10.1155/2023/4562974.

233. **Soni** et al., *In Silico Evaluation of Promising Naturally Occurring Bioactive Ligands Against Molecular Targets of SARS-Cov-2*, Proceedings of the National Academy of Sciences, India Section B: Biological Sciences, doi:10.1007/s40011-023-01496-x.

234. **Akter** et al., *Plausibility of natural immunomodulators in the treatment of COVID-19–A comprehensive analysis and future recommendations*, Heliyon, doi:10.1016/j.heliyon.2023.e17478.

235. **Rafiq** et al., *A Comprehensive Update of Various Attempts by Medicinal Chemists to Combat COVID-19 through Natural Products*, Molecules, doi:10.3390/molecules28124860.

236. **Badrunanto** et al., *In-silico approaches potential compounds in ginger (Zingiber officinale) as inhibitors of membrane, envelope, nucleocapsid, Plpro, and Helicase proteins of the SARS-CoV-2*, INTERNATIONAL CONFERENCE ON APPLIED COMPUTATIONAL INTELLIGENCE AND ANALYTICS (ACIA-2022), doi:10.1063/5.0127236.

237. **Sheikh** et al., *Promising roles of Zingiber officinale roscoe, Curcuma longa L., and Momordica charantia L. as immunity modulators against COVID-19: A bibliometric analysis*, Journal of Agriculture and Food Research, doi:10.1016/j.jafr.2023.100680.

238. **Corbo** et al., *Inhibitory potential of phytochemicals on five SARS-CoV-2 proteins: in silico evaluation of endemic plants of Bosnia and Herzegovina*, Biotechnology & Biotechnological Equipment, doi:10.1080/13102818.2023.2222196.

239. **Moura** et al., *Converging Paths: A Comprehensive Review of the Synergistic Approach between Complementary Medicines and Western Medicine in Addressing COVID-19 in 2020*, BioMed, doi:10.3390/biomed3020025.

240. **Fan** et al., *Pharmaceutical approaches for COVID-19: An update on current therapeutic opportunities*, Acta Pharmaceutica, doi:10.2478/acph-2023-0014.

241. **Srivastava (B)** et al., *A Brief Review on Medicinal Plants-At-Arms against COVID-19*, Interdisciplinary Perspectives on Infectious Diseases, doi:10.1155/2023/7598307.

242. **Nayak** et al., *Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease*, Journal of Personalized Medicine, doi:10.3390/jpm13040664.

243. **Giordano** et al., *Food Plant Secondary Metabolites Antiviral Activity and Their Possible Roles in SARS-CoV-2 Treatment: An Overview*, Molecules, doi:10.3390/molecules28062470.

244. **England** et al., *Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19*, Life, doi:10.3390/life13030617.

245. **Utomo** et al., *Revealing the Potency of Citrus and Galangal Constituents to Halt SARS-CoV-2 Infection*, MDPI AG, doi:10.20944/preprints202003.0214.v1.

246. **Nasirzadeh** et al., *Inhibiting IL-6 During Cytokine Storm in COVID-19: Potential Role of Natural Products*, MDPI AG, doi:10.20944/preprints202106.0131.v1.

247. **Khaerunnisa** et al., *Potential Inhibitor of COVID-19 Main Protease (M^{pro}) From Several Medicinal Plant Compounds by Molecular Docking Study*, MDPI AG, doi:10.20944/preprints202003.0226.v1.

248. **Mardaneh** et al., *Inhibiting NF-κB During Cytokine Storm in COVID-19: Potential Role of Natural Products as a Promising Therapeutic Approach*, MDPI AG, doi:10.20944/preprints202106.0130.v1.

249. **Paul** et al., *Herbs-derived phytochemicals – a boon for combating COVID-19*, Vegetos, doi:10.1007/s42535-023-00601-9.

250. **Guo** et al., *Enhanced compound-protein binding affinity prediction by representing protein multimodal information via a coevolutionary strategy*, Briefings in Bioinformatics, doi:10.1093/bib/bbac628.

251. **Supianto** et al., *Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature*, Journal of Taibah University Medical Sciences, doi:10.1016/j.jtumed.2022.12.015.

252. **Guerra** et al., *Critical Review of Plant-Derived Compounds as Possible Inhibitors of SARS-CoV-2 Proteases: A Comparison with Experimentally Validated Molecules*, ACS Omega, doi:10.1021/acsomega.2c05766.

253. **Chen (B)** et al., *The exploration of phytocompounds theoretically combats SARS-CoV-2 pandemic against virus entry, viral replication and immune evasion*, Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.11.022.

254. **Bijelić** et al., *Phytochemicals in the Prevention and Treatment of SARS-CoV-2—Clinical Evidence*, Antibiotics, doi:10.3390/antibiotics11111614.

255. **de Matos** et al., *Bioactive compounds as potential angiotensin-converting enzyme II inhibitors against COVID-19: a scoping review*, Inflammation Research, doi:10.1007/s00011-022-01642-7.

256. **Kushari** et al., *An integrated computational approach towards the screening of active plant metabolites as potential inhibitors of SARS-CoV-2: an overview*, Structural Chemistry, doi:10.1007/s11224-022-02066-z.

257. **Mousavi** et al., *Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies*, Canadian Journal of Infectious Diseases and Medical Microbiology, doi:10.1155/2022/2044282.

258. **Choe** et al., *The Efficacy of Traditional Medicinal Plants in Modulating the Main Protease of SARS-CoV-2 and Cytokine Storm*, Chemistry & Biodiversity, doi:10.1002/cbdv.202200655.

259. **Dinda** et al., *Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19*, European Journal of Medicinal Chemistry Reports, doi:10.1016/j.ejmcr.2022.100079.

260. **Rieder** et al., *A Review of In Silico Research, SARS-CoV-2, and Neurodegeneration: Focus on Papain-Like Protease*, Neurotoxicity Research, doi:10.1007/s12640-022-00542-2.

261. **Jamshidnia** et al., *An Update on Promising Agents against COVID-19: Secondary Metabolites and Mechanistic Aspects*, Current Pharmaceutical Design, doi:10.2174/1381612828666220722124826.

262. **Sagulkoo** et al., *Immune-Related Protein Interaction Network in Severe COVID-19 Patients toward the Identification of Key Proteins and Drug Repurposing*, Biomolecules, doi:10.3390/biom12050690.

263. **Sperry** et al., *Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients*, PLOS Computational Biology, doi:10.1371/journal.pcbi.1011050.

264. **Negru** et al., *Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses*, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432.

265. **Shahhamzehei** et al., *In Silico and In Vitro Identification of Pan-Coronaviral Main Protease Inhibitors from a Large Natural Product Library*, Pharmaceuticals, doi:10.3390/ph15030308.

266. **Ali** et al., *Implication of in silico studies in the search for novel inhibitors against SARS-CoV-2*, Archiv der Pharmazie, doi:10.1002/ardp.202100360.

267. **c19early.org (D)**, c19early.org/timeline.html.

268. **Mateja** et al., *The choice of viral load endpoint in early phase trials of COVID-19 treatments aiming to reduce 28-day hospitalization and/or death*, The Journal of Infectious Diseases, doi:10.1093/infdis/jiaf282.

269. **Zhang (B)** et al., *What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes*, JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690.

270. **Altman**, D., *How to obtain the P value from a confidence interval*, BMJ, doi:10.1136/bmj.d2304.

271. **Altman (B)** et al., *How to obtain the confidence interval from a P value*, BMJ, doi:10.1136/bmj.d2090.

272. **Sweeting** et al., *What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data*, Statistics in Medicine, doi:10.1002/sim.1761.

273. **Deng**, H., *PyMeta, Python module for meta-analysis*, www.pymeta.com/.